

Curriculum Vitae - David G. Birch, Ph.D.

Retina Foundation of the Southwest Telephone: (214) 363-3911 ext: 105
9600 North Central Expressway Email: dbirch@retinafoundation.org
Suite 200 Citizenship: U.S. Citizen
Dallas, Texas 75231 Date of Birth: 01/19/1949

EDUCATION

B.A. University of California, Riverside, California 1970
Ph.D. University of California, Santa Barbara, California 1978

POSITIONS

1978 - 1979 Post-doctoral fellow, University of Florida Medical School, Gainesville, Florida
1979 - 1982 Post-doctoral fellow, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
1982 - 2009 Research Director, Retina Foundation of the Southwest, Anderson Vision Res Center, Dallas, Texas
1982 – pres Director, Rose-Silverthorne Laboratory for Retinal Degenerations, Anderson Vision Res Center, Retina Foundation of the Southwest, Dallas, Texas
1982 - 1988 Adjunct Assistant Professor of Ophthalmol, University of Texas Southwestern Medical School, Dallas, Texas
1988 - 1994 Adjunct Associate Professor of Ophthalmol, University of Texas Southwestern Medical School, Dallas, Texas
1994 - pres Adjunct Professor of Ophthalmol, University of Texas Southwestern Medical School, Dallas, Texas
1999 – pres Center Coordinator, Foundation Fighting Blindness Southwest Regional Center
2004 – pres Director of Electrophysiology, University of Texas Southwestern Medical School, Dallas, Texas
2009 – 2016 Chief Scientific and Executive Officer, Retina Foundation of the Southwest, Dallas, Texas
2016 – pres Scientific Director, Retina Foundation of the Southwest

PROFESSIONAL ORGANIZATIONS

Association for Research in Vision and Ophthalmology
American Association for the Advancement of Science
Optical Society of America
American Academy of Ophthalmology
International Society for Clinical Electrophysiology of Vision
Southern Retina Study Group
International Society for Eye Research
FFB CRI Clinical Consortium – Executive Committee
Stephen J. Ryan Initiative for Macular Research - Executive Committee

PROFESSIONAL EXPERIENCE

Grants:

1978 - 1980 Post-doctoral fellowship, University of Florida Medical School
1980 - 1982 Post-doctoral fellowship, Massachusetts Eye and Ear Infirmary, Harvard Medical School
1984 - 2008 Principal Investigator, NEI 2R01 EY05235
"Retinal Pathophysiology in Infants and Adults"
1987 - 1992 Principal Investigator, NEI 1R01 EY07188
"Electroretinographic Studies in Age-related Macular Degeneration"
1987 - 1990 Co-Investigator, Cerebral Palsy Foundation
"Effect of Dietary Omega-3 Fatty Acids on Brain and Visual Development in Low Birth Weight Infants"

1996 – 2001 Co-Investigator, Food and Drug Administration FD-R-001232
 “DHA Supplementation and X-linked Retinitis Pigmentosa”

1987 - pres Principal Investigator, The Foundation Fighting Blindness, Inc.
 "Southwest Regional Center"

1987 - 2002 Co-Investigator, 1R01 HD22380
 "Are Omega-3 Fatty Acids Essential for Normal Development"

1991 - pres Principal Investigator, 1R01 EY09076
 "A measure of Human Receptor and Post-Receptor Activity"

1997 – 2001 Principal Investigator, TAP Holdings Inc.
 “The Use of Lansoprazole in Patients with Zollinger-Ellison Syndrome and Patients with Hypersecretion of Gastric Acid”

1997 – 1998 Consultant, Abbott Laboratories
 “Eye Findings in Patients Taking Ritonavir”

1997 – 1998 Principal Investigator, Pfizer Pharmaceuticals
 “A Double-Blind Randomized, Placebo-Controlled, Crossover Study to Investigate the Effects of a Single Oral Dose of Sildenafil (Placebo and 100 mg) on Visual Function in Subjects with Early Age-Related Macular Degeneration”

2003 – 2014 Food and Drug Administration, Co-Investigator
 “High Dose DHA and X-Linked Retinitis Pigmentosa: Phase II”

2006 – 2011 Neurotech USA, Lead Investigator
 A Phase II/III Study of Implants of Encapsulated Human NTC-201 Cells Releasing Ciliary Neurotrophic Factor (CNTF) for Participants with Retinitis Pigmentosa using Visual Field Sensitivity as the Primary Outcome Measure”

2007 – pres Second Sight Medical Products, Inc., Principal Investigator
 “Argus™ II Retinal Implant System Feasibility Protocol”

2007 – 2010 Centocor Research & Development, Inc., Principal Investigator
 “Phase I Open-Label, Non-Comparative Study Evaluating the Safety of a Single, Unilateral Subretinal Administration of CNTO 2476 in Advanced Retinitis Pigmentosa”

2007 – 2008 Acucela Inc., Principal Investigator
 “An Outpatient Study of the Retinal Safety and Systemic Tolerability of Orally Administered ACU-3223 After Single-Dosing and Repeated-Dosing in Healthy Adults of 55 to 75 Years of Age”

2008 – 2011 Allergan, Inc., Principal Investigator
 “An Exploratory, Multicenter, Patient-masked, Dose-escalation, Paired-eye Comparison, Sham-controlled, 6-Month (Plus 6-Month Extension) Study to Evaluate the Safety and Effects on Visual Function of 100 µg, 200 µg, and µg Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS) Applicator System in Patients with Retinitis Pigmentosa”

2012 – 2016 StemCell, Inc., Principal Investigator
 “Phase I/II safety and preliminary efficacy of human central nervous system stem cells (HuCNC-SC) subretinal transplantation in subjects with geographic atrophy of age-related macular degeneration”

2014 – 2016 Foundation Fighting Blindness Clinical Research Institute, Co- Investigator
 “Clinical evaluation of individuals with X-linked retinoschisis (XLRS)”

2012 – 2016 Foundation Fighting Blindness Clinical Research Institute, Co-Investigator
 “ProgSTAR, The natural history of the progression of atrophy secondary to Stargardt disease: a prospective longitudinal observational study”

2012 – 2015 Foundation Fighting Blindness Clinical Research Institute, Principal Investigator
 “A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Retinitis Pigmentosa Protocol #H-13371”

- 2015 – pres NightstaRX Ltd., Co-Investigator
“Observational Study Protocol NSR-CHM-OS1: Natural History of the Progression of Choroideremia Study (NIGHT)”
- 2015 – pres AGTC, Co-Investigator
“A multiple-site, Phase 1/2 safety and efficacy trial of a recombinant adeno-associated virus vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with x-linked retinoschisis”
- 2015 – pres Allergan, Principal Investigator
“A Phase I/IIa open-label, dose-escalation study of safety and tolerability of intravitreal RST-001 in patients with advanced retinitis pigmentosa (RP)”
- 2015 – pres Foundation Fighting Blindness Clinical Research Institute. Principal Investigator
“Rate of Progression in USH2A related retinal degeneration (RUSH2A)”
- 2015 – pres Ionis Pharmaceuticals, Principal Investigator
“Retinitis pigmentosa natural history study of patients with the P23H mutation of the rhodopsin gene”
- 2016 – pres NightstaRx Ltd, Principal Investigator
“A single-masked, randomized, controlled, parallel groups, Phase 3 clinical trial of retinal gene therapy for choroideremia using an adeno-associated viral vector (AAV2) encoding Rab escort protein 1 (REP1)”

Journal Referee:

Survey of Ophthalmol, Invest Ophthalmol Vis Sci, Journal of Comparative Psychology, American Journal of Ophthalmol, Doc Ophthalmol, Exp Eye Res, Ophthalmol, Vision Res, Arch Ophthalmol, Psychiatry Research, Vis Neurosci, Ophthalmic and Physiological Optics, Ophthalmic Genetics, Early Human Development, Neuron, Gene Therapy, Cell, Proc Nat Acad Sci., Brit J Ophthalmol, Graefe’s Archives, PlosOne, Translational Vision Science & Technology, Human Molecular Genetics, JAMA Ophthalmology.

Editorial Board:

Documenta Ophthalmologica, Experimental Eye Research

Service and Awards:

Adj. Professor of Ophthalmology; Director Visual Electrophysiology, University of Texas Southwestern Medical Center. Pro bono.

Head of Clinical Review Committee, Foundation Fighting Blindness.

Chair of DSMC; High Resolution Photoreceptor Imaging: A Novel Biomarker of Disease Progression and Treatment Response in Inherited Retinal Degenerations, UC San Francisco.

DSMC member; AAV2-hRPE65v2 treatment for Leber Congenital Amaurosis, Children’s Hospital of Philadelphia.

DSMC member; Transcorneal electrical stimulation for the treatment of retinitis pigmentosa – a safety and efficacy NSR device study, Wills Eye Institute, Philadelphia, PA.

Visual Sciences Study Section, NIH
 Small Business Innovation Research Program, 1988-1990
 Special Reviewer, VisA2 Study Section, 1990-1991
 Special Reviewer, VisC Study Section, 1991
 Special Reviewer, VisB Study Section, 1992
 Special Reviewer, VisC Study Section, 1993
 Regular Member, VisC Study Section, 1994-1997
 Special Emphasis Panels, 2000-present
 Special Reviewer, DPVS Study Section, 2012

Technical Program Committee, Optical Society of America, 1989-1990

Instructor, American Academy of Ophthalmology
Charles A. and Anne Morrow Lindbergh Certificate of Merit, 1994
2001 Achievement Award, American Academy of Ophthalmology
Scientific Advisor, D/FW Chapter, Foundation Fighting Blindness
Scientific Advisory Board, Dallas Services for Visually Impaired Children
Scientific Advisory Board, Foundation Fighting Blindness
Scientific Advisory Board, Academy of Biomedical Professions
Scientific Review Committee, Fight for Sight
2009 Fellow, Association for Research in Vision and Ophthalmology
Visionary Award, Foundation Fighting Blindness, April, 2012
Executive Committee, Beckman Initiative for Macular Research, 2013-present
Board of Directors Award, Foundation Fighting Blindness, June 2014
Executive Committee, FFB CRI Consortium, June 2016-present

Pre-doctoral fellows and interns:

Adriana Berezovsky, Mark Pennesi, Angela Peters, Janie Pantaglian, Megan Trese, Rachel Drennan, Hemaxi Patel, Erin Goin, Jane Gilmore, Brittany Holl, Kelley Locke, Salma Ferdous, Sydney Cooper, Kelly Kizer

Post-doctoral fellows:

Steven Nusinowitz, Ph.D., Radouil Tzekov, M.D., Ph.D., Jesus Gonzales, M.D., Alejandra Alcala, M.D., Liane Baidelman Kibel, M.D., Petra Kozma-Wiebe, M.D., Ph.D., Eugene Filley, Ph.D., Nalini Rangaswamy Ph.D., Yuquan (Eddie) Wen Ph.D., Lea Bennett Ph.D.

PUBLICATIONS

Books:

Fuller DG and Birch DG. Assessment of Visual Function for the Clinician. Ophthalmology Clinics of North America, W.B. Saunders Co., Philadelphia, PA. September, 1989.
Fishman GA, Birch DG, Harding GE, Brignell MG. Electrophysiologic Testing. American Academy of Ophthalmology, San Francisco, CA. December, 2000.

Book Reviews:

Birch DG. Atlas of Fundus Autofluorescence (Holz FG, Schmitz-Valckenberg S, Spaide RF, Bird AC, eds). Springer-Verlag, Berlin, 2007. ISBN: 978-3-540-71993-9

Articles:

1. Jacobs GH and Birch DG. Increment-threshold functions for different rodent species. Vision Res, 1975; **15**:375-378.
2. Birch DG and Jacobs GH. Behavioral measures of rat spectral sensitivity. Vision Res, 1975; **15**: 687-691.
3. Birch DG and Jacobs GH. Effects of constant illumination on vision in the albino rat. Physiology and Behavior, 1977; **19**:255-259.
4. Birch DG and Jacobs GH. Spatial contrast sensitivity in albino and pigmented rats. Vision Res, 1979; **19**:933-937.
5. Birch DG and Jacobs GH. The effects of prolonged dark exposure on visual thresholds in young and adult rats. Invest Ophthalmol Vis Sci, 1979; **18**:752-756.
6. Enoch JM, Birch DG, and Birch EE. Monocular light exclusion for a period of days reduces directional sensitivity of the human retina. Science, 1979; **206**:705-709.

7. Birch DG and Jacobs GH. Light-induced damage to photopic and scotopic mechanisms in the rat depends upon rearing conditions. Experimental Neurology, 1980; **68**:269-283.
8. Birch DG, Birch EE, and Enoch JM. Visual sensitivity, resolution, and Rayleigh matches following monocular occlusion for one week. J Opt Soc Am, 1980; **70**:954-958.
9. Enoch JM, Birch DG, Birch EE, and Benedetto MD. The effect of unocular occlusion on selected visual functions. Transactions of the Ophthalmological Societies of the United Kingdom, 1980; **99**:407-412.
10. Enoch JM and Birch DG. Evidence for alteration in photoreceptor orientation. Ophthalmol, 1980; **87**:821-834.
11. Enoch JM, Birch DG, Birch EE, and Benedetto MD. Alteration in directional sensitivity of the retina by monocular occlusion. Vision Res, 1980; **20**:1185-1189.
12. Fitzgerald CR, Enoch JM, Birch DG, Benedetto MD, Temme LA, and Dawson WW. Anomalous pigment epithelial/photoreceptor relationships and receptor orientation. Invest Ophthalmol Vis Sci, 1980; **19**:956-966.
13. Fitzgerald CR, Birch DG, and Enoch JM. Functional analysis of vision in patients after retinal detachment repair. Arch Ophthalmol, 1980; **98**:1237-1244.
14. Enoch JM and Birch DG. Inferred positive phototropic activity in human photoreceptors. Philos Trans R Soc Lond B Biol Sci, B, 1981; **291**:323-351.
15. Birch DG, Sandberg MA, and Berson EL. The Stiles-Crawford effect in retinitis pigmentosa. Invest Ophthalmol Vis Sci, 1982; **22**:157-164.
16. Birch DG and Sandberg MA. Psychophysical studies of cone optical bandwidth in patients with retinitis pigmentosa. Vision Res, 1982; **22**:1113-1117.
17. Jacobs GH, Birch DG, and Blakeslee B. Visual acuity and spatial contrast sensitivity in tree squirrels. Behav Proc, 1982; **7**:367-375.
18. Stromeyer CF, Mulligan JB, Birch DG, and Dawson BM. Adaptation to polarized light in humans. Vision Res, 1982; **22**:217-223.
19. Marmor MF, et al. Retinitis Pigmentosa. A symposium on terminology and methods of examination. Ophthalmol, 1983; **90**:126-131.
20. Birch DG, Berson EL, and Sandberg MA. Diurnal rhythm in the human rod ERG. Invest Ophthalmol Vis Sci, 1984; **25**:236-238.
21. Berson EL, Sandberg MA, Rosner B, Birch DG, and Hanson AH. Natural course of retinitis pigmentosa over a three year interval. American Journal of Ophthalmol, 1985; **99**:240-251.
22. Enoch JM and Birch DG. Comment on inferred positive phototropic activity in human photoreceptors. Philos Trans R Soc Lond B Biol Sci of London, B, 1985; **309**:611-613.
23. Birch DG, Sandberg MA, and Berson EL. Diurnal rhythm in the human rod ERG: relationship to cyclic lighting. Investigative Ophthalmol, 1986; **27**:268-270.
24. Birch DG, and Fish GE. Rod ERGs in children with hereditary retinal degeneration. J Pediatr Ophthalmol Strabismus, 1986; **23**:227-232.
25. Fish GE, Birch DG, Fuller DW, and Straach R. A comparison of visual function tests in eyes with maculopathy. Ophthalmol, 1986; **93**:1177-1182.
26. Birch DG. Diurnal rhythm in the rod ERG in retinitis pigmentosa and cone-rod degeneration. Vision Science and Its Applications, Vol. 1, OSA Technical Digest Series (Optical Society of America, Washington, D.C.) 1987; 50-52
27. Birch DG and Fish GE. Rod ERGs in retinitis pigmentosa and cone-rod degeneration. Invest Ophthalmol Vis Sci, 1987; **28**:140-150.
28. Birch EE, Hale LA, Stager DR, Fuller DG, and Birch DG. Operant acuity of toddlers and developmentally delayed children with low vision. J Pediatr Ophthalmol Strabismus, 1987; **24**:164-169.
29. Birch EE and Birch DG. Pupillometric measures of retinal sensitivity in infants and adults with retinitis pigmentosa. Vision Res, 1987; **27**:499-505.

30. Birch DG, Herman WK, deFaller JM, Disbrow DT, and Birch EE. The relationship between rod perimetric thresholds and full-field rod ERGs in retinitis pigmentosa. Invest Ophthalmol Vis Sci, 1987; **28**:954-965.
31. Birch DG and Sandberg MA. Dependence of cone b-wave implicit time on rod amplitude in retinitis pigmentosa. Vision Res, 1987; **27**:1105-1112.
32. Birch DG. Diurnal rhythm in the human rod ERG: retinitis pigmentosa. Invest Ophthalmol Vis Sci, 1987; **28**:2042-2048.
33. Enoch JM, Hamer RD, Lakshminarayanan V, Yasuma T, Birch DG, and Yamade S. Effect of monocular light exclusion on the Stiles-Crawford Function. Vision Res, 1987; **27**:507-510.
34. Birch DG and Fish GE. Focal cone ERGs: aging and macular disease. Doc Ophthalmol, 1988; **69**:211-220.
35. Birch DG, Birch EE and Uauy RD. ERGs and VEPs in very low birth weight (VLBW) infants. *Topical Vision Science and Its Applications*, Vol. 1, OSA Technical Digest Series (Optical Society of America, Washington, D.C.) 1988; 94-97.
36. Birch DG, Jost BF, and Fish GE. The focal electroretinogram in fellow eyes of patients with idiopathic macular holes. Arch Ophthalmol, 1988; **106**:1558-1563.
37. Birch DG. Clinical electroretinography. In Fuller, D.G. and Birch, D.G. (Eds.) Assessment of Visual Function for the Clinician. W.B. Saunders Co., Philadelphia, PA., 1989.
38. Fish GE and Birch DG. The focal electroretinogram in the clinical assessment of macular function. Ophthalmol, 1989; **96**:109-114.
39. Birch DG and Jost BF. Prospective measures of the focal ERG in fellow eyes of patients with a full-thickness macular hole. *Vision Science and Its Applications*, Vol. 1, OSA Technical Digest Series (Optical Society of America, Washington, D.C.) 1989; 272-275.
40. Birch DG and Anderson JL. Rod visual fields in cone-rod degeneration: comparisons to retinitis pigmentosa. Invest Ophthalmol Vis Sci, 1990; **31**:2288-2299.
41. Birch EE, Birch DG, Uauy R, and Petrig B. Retinal and cortical function of very low birth weight infants at 36 and 57 weeks post-conception age. Clinical Vision Res, 1990; **5**:363-373.
42. Hood DC and Birch DG. The a-wave of the ERG as a quantitative measure of human receptor activity. *Vision Science and Its Applications*, Vol. 1, OSA Technical Digest Series (Optical Society of America, Washington, D.C.) 1990; 66-69.
43. Birch DG and Anderson JL. Rod visual fields in cone-rod degeneration: Comparisons to retinitis pigmentosa. *Vision Science and Its Applications*, Vol. 1, OSA Technical Digest Series (Optical Society of America, Washington, D.C.) 1990; 36-39.
44. Birch EE, Birch DG, and Uauy R. Effects of gestational age at birth and diet on visual acuity. *Vision Science and Its Applications*, Vol. 1, OSA Technical Digest Series (Optical Society of America, Washington, D.C.) 1990; 14-17.
45. Fish GE, Jost BF, Snyder WB, Fuller DG, Birch DG. Cataract extraction after brachytherapy for malignant melanoma of the choroid. Ophthalmol, 1990; **98**:843-847.
46. Hood DC and Birch DG. The relationship between models of receptor activity and the a-wave of the human ERG. Clinical Vision Res, 1990; **5**:293-297.
47. Hood DC and Birch DG. The a-wave of the human electroretinogram and rod receptor function. Invest Ophthalmol Vis Sci, 1990; **31**:2070-2081.
48. Hood DC and Birch DG. A quantitative measure of the electrical activity of human rod photoreceptors using electroretinography. Vis Neurosci, 1990; **5**:379-387.
49. Jost BF, Hutton WL, Fuller DG, Vaiser A, Snyder WB, Fish GE, Spencer R, and Birch DG. Vitrectomy in eyes at risk for macular hole formation. Ophthalmol, 1990; **97**:843-847.
50. Uauy R, Birch DG, Birch EE, Tyson J, and Hoffman D. Effect of dietary omega-3 fatty acids on retinal function of very low birth weight neonates. Pediatric Research, 1990; **28**:485-492.
51. Birch DG, Anderson JL, and Fish GE. Longitudinal measures in children receiving ENCAD for hereditary retinal degeneration. Doc Ophthalmol, 1991; **77**:185-191.

52. Hood DC and Birch DG. An evaluation of the ERG b-wave as a measure of inner nuclear layer activity: Implications for Naka-Rushton fits. *Vision Science and Its Applications*, Vol. 1, OSA Technical Digest Series (Optical Society of America, Washington, D.C.) 1991; 2-5.
53. Birch EE, Birch DG, and Uauy RD. Maturation of the oscillatory potentials of the human electroretinogram. *Vision Science and Its Applications*, Vol. 1, OSA Technical Digest Series (Optical Society of America, Washington, D.C.) 1991; 28-31.
54. Birch DG, Birch EE, Hoffman DR, and Uauy RD. Effects of dietary Omega-3 fatty acids on rod ERG Function in very-low-birth-weight neonates. *Vision Science and Its Applications*, Vol. 1, OSA Technical Digest Series (Optical Society of America, Washington, D.C.) 1991; 32-35.
55. Swanson WH and Birch DG. SWS-Cone defects in photoreceptor degenerations. *Vision Science and Its Applications*, Vol. 1, OSA Technical Digest Series (Optical Society of America, Washington, D.C.) 1991; 208-211.
56. Birch DG. Focal electroretinography. In Heckenlively, J. and Arden, G. (Eds.) Principles and Practice of Clinical Electroretinography of Vision. Mosby Year Book, Inc., St. Louis MO., 1991.
57. Birch DG. Flicker electroretinography. In Heckenlively, J. and Arden, G. (Eds.) Principles and Practice of Clinical Electroretinography of Vision. Mosby Year Book, Inc., St. Louis MO., 1991.
58. Hood DC and Birch DG. Models of human rod photoreceptors and the ERG. In Landy, M. and Movshon, A. (Eds.) Computational Models of Visual Processing. MIT Press, Boston, MA., 1991; 57-67.
59. Birch DG, Anderson JL, Fish GE, and Jost BF. Pattern-reversal electroretinographic acuity in untreated eyes with subfoveal neovascular membranes. Invest Ophthalmol Vis Sci. 1992; **33**:2097-2104.
60. Birch DG, Birch EE, Hoffman DR, and Uauy RD. Retinal development in very-low-birth-weight infants fed diets differing in omega-3 fatty acids. Invest Ophthalmol Vis Sci, 1992; **33**:2365-2376.
61. Hood DC and Birch DG. A model of the human ERG: Predicting changes in a- and b-wave amplitude and timing with congenital stationary nightblindness. *Vision Science and Its Applications*, Vol. 1, OSA Technical Digest Series (Optical Society of America, Washington, D.C.) 1992; 57-60.
62. Birch EE, Birch DG, Hoffman DR, and Uauy R. Dietary essential fatty acid supply and visual acuity development. Invest Ophthalmol Vis Sci, 1992; **33**:3242-3253.
63. Birch DG and Anderson JL. Standardized full-field ERGs: normal values and their variation with age. Arch Ophthalmol, 1992; **110**:1571-1576.
64. Hood DC and Birch DG. A computational model of the amplitude and implicit time of the b-wave of the human ERG. Vis Neurosci, 1992; **8**:107-126.
65. Snyder WB, Bloome MA, and Birch DG. Pneumatic retinopexy vs. scleral buckle- Preferences of Vitreous Society members- 1990. Retina, 1992; **12**:43-45.
66. Uauy R, Birch D, Birch E, Tyson J, and Hoffman, D. Are omega-3 fatty acids required for normal eye and brain development of the very low birth weight infant? In Koletzko, B. (Ed.) Recent Advances in Infant Feeding. Verlag, New York, 1992, pp 13-21.
67. Uauy R, Birch DG, Birch EE, and Hoffman DR. Essential fatty acid requirements for normal visual and neural development. In Hernandez, M and Argente, J. (Eds.) Human Growth: Basic and Clinical Aspects. Elsevier Science Publishers, New York, N.Y., 1992; 197-203.
68. Uauy R, Birch EE, Birch DG, and Peirana P. Visual and brain function measurements in studies of n-3 fatty acid requirements of infants. Journal of Pediatrics. 1992; **120**:168-180.
69. Birch DG, Anderson JL, Fish GE, and Jost BF. Pattern-reversal electroretinographic follow-up of laser photocoagulation for subfoveal neovascular lesions in age-related macular degeneration. American Journal of Ophthalmol, 1993; **116**:148-155.
70. Birch EE, Birch DG, Uauy R. Visual function and the essentiality of α -linolenic acid and docosahexaenoic acid in human infants. In Yehuda S and Mostofsky DI (Eds) Handbook of Essential Fatty Acid Biology: Biochemistry, Physiology, and Behavioral Neurobiology.

Humana Press, Inc., Totowa, NJ, 1993

71. Birch DG, Anderson JL, and Birch EE. Early abnormalities of rod function in children with X-linked retinitis pigmentosa. Clinical Vision Sciences, 1993; **8**:329-335.
72. Birch DG and Anderson JL. Yearly rates of rod and cone functional loss in retinitis pigmentosa and cone-rod degeneration. *Vision Science and Its Applications*, Vol. 3, OSA Technical Digest Series (Optical Society of America, Washington, D.C.), 1993; 334-337.
73. Hood DC and Birch DG. Interpretations of Naka-Rushton parameters from patients with adRP and CRD. *Vision Science and Its Applications*, Vol. 3, OSA Technical Digest Series (Optical Society of America, Washington, D.C.), 1993; 338-341.
74. Birch EE, Birch DG, Hoffman D, Hale L, Everett M, and Uauy R. Breast feeding and optimal visual development. J Pediatr Ophthalmol Strabismus, 1993; **30**:33-38.
75. Hoffman DR, Birch EE, Birch DB, and Uauy R. Effects of supplementation with ω -3 long-chain polyunsaturated fatty acids on retinal and cortical development in premature infants. Amer J Clinical Nutrition. 1993; **57**:8075-8125.
76. Hoffman DR, Uauy R, and Birch DG. Red blood cell fatty acid levels in patients with autosomal dominant retinitis pigmentosa. Exp Eye Res, 1993; **57**:359-368.
77. Hood DC, Birch DG, and Birch EE. The use of models to improve hypothesis delineation. A study of infant electroretinography. In Simons, K. (Ed.) Early Visual Development: Normal and Abnormal. Committee on Vision, Commission on Behavioral and Social Sciences and Education, National Research Council. Oxford University Press, New York, 1993; pp 517-535.
78. Hood DC and Birch DG. Light adaptation of human rod receptors: The leading edge of the human a-wave and models of rod receptor activity. Vision Res, 1993; **33**:1605-1618.
79. Hood DC, Shady S, and Birch DG. Heterogeneity in retinal disease and the computational model of the human-rod response. J Opt Soc Am, A, 1993; **10**:1624-1630.
80. Hood DC and Birch DG. Human cone receptor activity: the leading edge of the a-wave and models of receptor activity. Vis Neurosci, 1993; **10**:857-871.
81. Rodriguez JA, Herrera CA, Birch DG, and Daiger SP. A leucine to arginine amino acid substitution at codon 46 of rhodopsin is responsible for a severe form of autosomal dominant retinitis pigmentosa. Hum Mut, 1993; **2**:205-213.
82. Swanson WH, Birch DG, and Anderson JL. S-cone function in patients with retinitis pigmentosa. Invest Ophthalmol Vis Sci, 1993; **34**:3045-3055.
83. Uauy R, Birch DG, Birch EE, Hoffman D, and Tyson J. Effect of dietary essential ω -3 fatty acids on retinal and brain development in premature infants. In Sinclair, A. and Gibson, R. (Eds.) Essential Fatty Acids and Eicosanoids. American Oil Chemists' Society, Champaign, IL., 1993; pp 197-202.
84. Uauy R, Birch DG, Birch EE, Hoffman DR, and Tyson J. Visual and brain development in infants as a function of essential fatty acid supply provided by the early diet. Lipids, Learning, and the Brain: Fats in Infant Formulas (J. Dobbing, J.D. Benson, eds.) Ross Laboratories, Columbus, OH, 1993; 215-232.
85. Hood DC, Shady S, and Birch DG. Understanding changes in the b-wave of the ERG caused by heterogeneous receptor damage. Invest Ophthalmol Vis Sci, 1994; **35**:2477-2488.
86. Hood DC and Birch DG. Rod phototransduction in retinitis pigmentosa: Estimation and interpretation of parameters derived from the rod a-wave. Invest Ophthalmol Vis Sci, 1994; **35**:2948-2961.
87. Birch DG, Hood DC, Nusinowitz S, and Pepperberg DR. Recovery from activation in human rods. *Vision Science and Its Applications*, Vol. 2, OSA Technical Digest Series (Optical Society of America, Washington, D.C.), 1994; 272-275.
88. Hood DC and Birch DG. The human rod a-wave and transduction: Interpreting the fit of the Lamb and Pugh model. *Vision Science and Its Applications*, Vol. 2, OSA Technical Digest Series (Optical Society of America, Washington, D.C.), 1994; 268-271.
89. Uauy R, Hoffman DR, Birch EE, Birch DG, Jameson DM, and Tyson J. Safety and efficacy

- of omega-3 fatty acids in the nutrition of very low birth weight infants: soy oil and marine oil supplementation of formula. J Pediatrics, 1994; **124**:612-620.
90. Uauy-Dagach R, Birch EE, Birch DG, and Hoffman DR. Significance of ω 3 fatty acids for retinal and brain development of preterm and term infants. World Review of Nutrition and Dietetics, 1994; **75**:52-62.
 91. Uauy R, Birch DG, Hoffman DR, and Birch EE. Omega-3 fatty acids: essential nutrients for optimal retinal and brain development. *Omega-3 Fatty Acids in Nutrition, Vascular Biology, and Medicine*, (H. J. Pournall and A. A. Spector, editors), 1994; 33-46.
 92. Birch DG, Hood DC, Nusinowitz S, and Pepperberg DR. Abnormal activation and inactivation of rod transduction in patients with autosomal dominant retinitis pigmentosa and the pro-23-his mutation. Invest Ophthalmol Vis Sci, 1995; **36**:1603-1614.
 93. Birch DG and Hood DC. Abnormal rod photoreceptor function in retinitis pigmentosa. *Degenerative Diseases of the Retina*, (R. Anderson, J. Hollyfield, and M. LaVail, editors), Plenum, New York, 1995; 359-369.
 94. Hoffman DR and Birch DG. Docosahexaenoic acid in red blood cells of patients with x-linked retinitis pigmentosa. Invest Ophthalmol Vis Sci, 1995; **36**:1009-1018.
 95. Pepperberg DR, Hood DC, and Birch DG. Light adaptation and post-flash recovery in human rods. *Vision Science and Its Applications*, Vol. 1, OSA Technical Digest Series (Optical Society of America, Washington, D.C.), 1995; 268-271.
 96. Hood DC and Birch DG. Retinitis pigmentosa affects cone transduction as well as post-synaptic cone activity. *Vision Science and Its Applications*, Vol. 1, OSA Technical Digest Series (Optical Society of America, Washington, D.C.) 1995; 272-275.
 97. Hoffman DR, Uauy R, and Birch DG. Docosahexaenoic acid abnormalities in red blood cells of patients with retinitis pigmentosa. *Degenerative Disease of the Retina* (R. Anderson, J. Hollyfield, and M. LaVail, editors), Plenum, New York, 1995; 385-393.
 98. Hoffman DR, Uauy R, and Birch DG. Metabolism of omega-3 fatty acids in patients with autosomal dominant retinitis pigmentosa. Exp Eye Res, 1995; **60**:279-289.
 99. Hood DC and Birch DG. Computational models of rod-driven retinal activity. IEEE Engineering in Medicine and Biology, 1995; **14**:59-66.
 100. Hood DC and Birch DG. Phototransduction in human cones measured using the a-wave of the ERG. Vision Res, 1995; **35**:2801-2810.
 101. Hood DC and Birch DG. Abnormal cone receptor activity in patients with hereditary degeneration. *Degenerative Disease of the Retina* (R. Anderson, J. Hollyfield, and M. LaVail, editors), Plenum, New York, 1995; 349-358.
 102. Swanson WH, Lynn JR, Fellman RL, Starita RJ, Schumann SP, Birch DG, Nusinowitz S. Inter-operator variability in images obtained by laser ellipsometry of the nerve fiber layer. *Journal of Glaucoma*, 1995; **4**:414-418
 103. Nusinowitz S, Hood DC, and Birch DG. Rod transduction parameters from a-waves of local receptor populations. J Opt Soc Am, 1995; **12**:2259-2266.
 104. Shady S, Hood DC, and Birch DG. Rod phototransduction in retinitis pigmentosa: distinguishing alternative mechanisms of degeneration. Invest Ophthalmol Vis Sci, 1995; **36**:1027-1037.
 105. Uauy R, De Andraca I, Mena P, Birch D, Birch E. New approaches to evaluate the effect of nutrition on brain and nutritional development. Nutrition in a Sustainable Environment, IUNS Proceedings of the XV International Nutrition Congress. Smith, Gordon and Co., London. 1995; 466-470.
 106. Hood DC and Birch DG. The b-wave of the scotopic electroretinogram as a measure of the activity of human on-bipolar cells. J Opt Soc Am, 1996; **13**:623-633.
 107. Hood DC and Birch DG. Abnormalities of the retinal cone system in retinitis pigmentosa. Vision Res, 1996; **36**:1699-1709.
 108. Birch DG, Pepperberg DR, and Hood DC. The effects of light adaptation on recovery kinetics of

- the human rod photoresponse. *Vision Science and Its Applications*, Vol. 1, OSA Technical Digest Series (Optical Society of America, Washington, D.C.) 1996; 60-63.
109. Hood DC, Birch DG, and Pepperberg DR. The trailing edge of the photoresponse from human cones derived using a two-flash paradigm. *Vision Science and Its Applications*, Vol. 1, OSA Technical Digest Series (Optical Society of America, Washington, D.C.) 1996; 64-67.
 110. Pepperberg DR, Birch DG, Hofman KP, and Hood DC. Recovery kinetics of human rod photoresponses: A model suggested by the two-branched "saturation function." *Vision Science and Its Applications*, Vol. 1, OSA Technical Digest Series (Optical Society of America, Washington, D.C.) 1996; 68-71.
 111. Birch EE, Hoffman DR, Birch DG, Uauy R, Bane M, Castañeda Y, and Prestidge C: Visual Acuity Development of Term Infants fed ω 3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplemented Formula. *Vision Science and Its Applications*, Vol. 1, OSA Technical Digest Series (Optical Society of America, Washington, D.C.) 1996; 2-5.
 112. Pepperberg DR, Birch DG, Hofmann KP, and Hood DC. Recovery kinetics of human rod phototransduction inferred from the two-branched a-wave "saturation function." *J Opt Soc Am*, 1996; **13**:586-600.
 113. Uauy R, Peirano P, Hoffman D, Mena P, Birch D, and Birch E. Role of essential fatty acids in the function of the developing nervous system. *Lipids*, 1996; **31**:S167-S176.
 114. Hoffman DR, Birch EE, Birch DG, and Uauy R. Dietary long-chain polyunsaturates (LCPs) for preterm and term infants? Controversies in visual function outcomes. In: *International Congress and Symposium Series 215: Major Controversies in Infant Nutrition* (Edited by T. F. David), Royal Society of Medicine Press, Ltd., 1996, pp.45-55.
 115. Kedzierski W, Lloyd M, Birch DG, Bok D, and Travis GH. "Generation and analysis of transgenic mice expressing P216L-substituted rds/peripherin in rod photoreceptors." *Invest Ophthalmol Vis Sci*, 1997; **38**:498-509.
 116. Birch DG, Travis GH, Locke KG, Hood DC. Rod ERGs in mice and humans with putative null mutations in the RDS Gene. *Vision Science and Its Applications*, Vol. 1, OSA Technical Digest Series (Optical Society of America, Washington, D.C.) 1997; 262-265.
 117. Birch EE, Birch DG, and Uauy R. Visual function and the essentiality of α -linolenic acid and docosahexaenoic acid in human infants. *Fatty Acids: Biochemistry and Behavior*. (S.Yehuda and D.I. Mostovsky, editors), 1997, pp. 183-199.
 118. Pepperberg DR, Birch DG, and Hood DC. Photoresponses of human rods *in vivo* derived from paired-flash electroretinograms. *Vis Neurosci*, 1997; **14**:73-82.
 119. Kennedy KA, Ipson MA, Birch DG, Tyson JE, Anderson JL, Nusinowitz S, West L, Spencer R, and Birch EE. Light reduction and the electroretinogram of preterm infants. *Arch Dis Child Fetal Neonatal Ed*, 1997; **3**:168-173. PMC: 1720640.
 120. Nusinowitz S and Birch DG. Topography of rod and cone sensitivity loss in retinitis pigmentosa. *Basic and Clinical Applications of Visual Science*. (V. Lakshminarayanan, editor) Doc Ophthalmol Proceedings Series, 1997; **60**: 227-230.
 121. Birch DG and Sandberg MA. Acquisition of submicrovolt full-field cone ERGs; artifacts and reproducibility. *Doc Ophthalmol*, 1997; **92**:269-280.
 122. Bennett MJ, Boriack RL, and Birch DG. In utero and post-delivery supplementation of motor neuron degeneration mutant mice with polyunsaturated fatty acids does not alter the clinical or pathological course. *Neuropediatrics*, 1997; **28**:82-84.
 123. Locke KG, Hoffman DR, Wheaton, DH, Fish GE, and Birch DG. Description of ongoing trial with fatty acid supplementation in X-linked retinitis pigmentosa. *J Ophthalm Photog*, 1997; **19**:27-31.
 124. Hood DC and Birch DG. Assessing abnormal rod photoreceptor activity with the a-wave of the ERG: Applications and methods. *Doc Ophthalmol*, 1996; **92**:253-267.
 125. Buraczynska M, Wu W, Fujita R, Buraczynska K, Phelps E, Andreasson S, Bennett J, Birch DG, Fishman GA, Hoffman DR, Inana G, Jacobson SG, Musarella MA, Sieving PA, and Swaroop A.

- Spectrum of mutations in the RPGR gene that are identified in 20% of patients with X-linked retinitis pigmentosa. Am J Human Genetics, 1997; **61**:1287-1292. PMC: 1716085.
126. Nusinowitz S, Birch DG, and Birch EE. Rod photoresponses in 6-week and 4-month old human infants. Vision Res, 1998; **38**:627-635.
 127. Boycott KM, Pearce WG, Musarella MA, Weleber RG, Maybaum TA, Birch DG, Miyake Y, Young RSL, and Bech-Hansen NT. Evidence for genetic heterogeneity in X-linked congenital stationary night blindness. Am J Human Genetics, 1998; **62**:865-875.
 128. Hoffman DR and Birch DG. Omega-3 fatty acid status in patients with retinitis pigmentosa. World Review of Nutrition and Diet, 1998; **83**:52-60.
 129. Birch EE, Hoffman DR, Uauy R, Birch DG, and Prestidge C. Visual acuity and the essentiality of docosahexaenoic and arachidonic acid in the diet of term infants. Pediatric Research, 1998; **44**:201-209.
 130. Sohocki MM, Sullivan LS, Mintz-Hittner HA, Birch DG, Heckenlively JR, Freund CL, McInnes RR, and Daiger SP. A range of clinical phenotypes associated with mutations in CRX, a photoreceptor transcription-factor gene. Am J Human Genetics, 1998; **63**:1307-1315.
 131. Gieser L, Fujita R, Goring HHH, Ott J, Hoffman DR, Cideciyan AV, Birch DG, Jacobson SG, Swaroop A. A novel locus (RP24) for X-linked retinitis pigmentosa maps to Xq26-27. Am J Human Genetics, 1998; **63**:1439-1447.
 132. Birch DG, Anderson JL, and Fish GE. Yearly rates of rod and cone functional loss in retinitis pigmentosa and cone-rod degeneration. Ophthalmol, 1999; **106**:258-268.
 133. Peña M, Birch DG, Uauy R, and Peirano P. The effect of sleep state on electroretinographic (ERG) activity during early human development. Early Human Development, 1999; **55**:51-62.
 134. Birch DG. Retinal degeneration in retinitis pigmentosa (RP) and neuronal ceroid lipofuscinosis (NCL): an overview. Mol Genet Metab, 1999; **66**:356-366.
 135. Hoffman DR, Birch EE, Birch DG, and Uauy R. Fatty acid profile of buccal cheek cell phospholipids as an index for dietary intake of docosahexaenoic acid in premature infants, Lipids 1999; **34**:337-342.
 136. Birch DG. ERG measures of photoreceptor deactivation in retinitis pigmentosa. Dig J Ophthalmol, 1999; **5**:1-11.
 137. Yang R-B, Robinson SW, Xiong W-H, Yau K-W, Birch DG, Garbers DL. Disruption of a retinal guanylyl cyclase gene leads to cone-specific dystrophy and paradoxical rod behavior. J Neurosci, 1999; **19**:5889-5897.
 138. Benson WE, Chan P, Sharma S, Snyder WB, Bloome MA, Birch DG. Current popularity of pneumatic retinopexy. Retina, 1999; **19**:238-41.
 139. Weng J, Mata NL, Azarian SM, Tzekov RT, Birch DG, Travis GH. Insights into the function of rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in *abcr* knockout mice. Cell, 1999; **98**:1-20.
 140. Bowne SJ, Daiger SP, Hims MM, Sohocki MM, Malone KA, McKie AB, Heckenlively JR, Birch DG, Inglehearn CF, Bhattacharya SS, Bird A, Sullivan LS. Mutations in the RP1 gene causing autosomal dominant retinitis pigmentosa. Hum Mol Genet, 1999, **8**:2121-2128. PMC: 2585827.
 141. Birch DG, Yang R-B, Robinson SW, Garbers DL. Loss of cone and reduction in rod ERG responses in the guanylyl cyclase-E (GC-E) deficient mouse. *Degenerative Disease of the Retina* (R. Anderson, J. Hollyfield, and M. LaVail, editors), Plenum, New York, 1999; 67-80.
 142. Pepperberg DR, Birch DG, Hood DC. Electroretinographic determination of the human rod flash response *in vivo*. Methods in Enzymology, 2000; **316**:202-223.
 143. Wang YW, Birch DG. Local and global visual function deficits in patients with ABCR gene mutations. OSA Trends in Optics and Photonics, Vol. 35, *Vision Science and Its Applications* (Optical Society of America, Washington, D.C.) 2000; 77-84.
 144. Birch DG, Peters AY, Locke KL, Megarity CF, Travis GH. Visual function in patients with cone-rod dystrophy (CRD) associated with ABCR gene mutations. OSA Trends in Optics and Photonics, Vol.

- 35, *Vision Science and Its Applications* (Optical Society of America, Washington, D.C.) 2000; 97-100.
145. Birch EE, Garfield S, Hoffman DR, Uauy R, Birch DG. A randomized controlled trial of early dietary supply of long chain polyunsaturated fatty acids and mental development in term infants. Dev Med Child Neurol, 2000; 42: 174-181.
 146. Clarke G, Goldberg AFX, Vidgen D, Collins L, Schwarz L, Ploder L, Molday LL, Rossant J, Molday RS, Birch DG, McInnes RR. Rom-1 is required for rod photoreceptor viability and the regulation of disk morphogenesis. Nat Genet, 2000; **25**:67-73.
 147. Sohocki MM, Bowne SJ, Sullivan LS, Blackshaw S, Cepko CL, Payne AM, Bhattacharya SS, Khaliq S, Mehdi SQ, Birch DG, Harrison WR, Elder FFB, Heckenlively JR, Daiger SP. Mutations in a new photoreceptor-pineal gene on 17p cause Leber congenital amaurosis. Nat Genet, 2000, **24**:79-83. PMID: 10927016; PMC: 2581448.
 148. Tzekov RT, Sohocki MM, Daiger SP, Birch DG. Visual phenotype in patients with Arg41Gln and Ala196+1bp mutations in the CRX gene. Ophthalmic Genet, 2000; 21:89-99. PMID: 10916183.
 149. Peters AY, Locke KG, Birch DG. Comparison of the Goldmann-Weekers Dark Adaptometer™ and LKC Technologies Scotopic Sensitivity Tester-1™. Doc Ophthalmol, 2000; 101:1-10. PMID: 11128963
 150. Bowne SJ, Sullivan LS, Ding L, Traer E, Prescott SM, Birch DG, Heckenlively JR, Kennan A, Humphries P, Daiger SP. Evaluation of human diacylglycerol kinase, DGK1, a homolog of *Drosophila rdgA*, in inherited retinopathy mapping to 7q. Molecular Vision, 2000; **22**:6-9. PMC: 2583079.
 151. Swanson WH, Felius J, Birch DG. Effect of stimulus size on static visual fields from patients with retinitis pigmentosa. Ophthalmology, 2000; 107:1950-1954. PMID: 11013205.
 152. Sohocki MM, Perrault I, Leroy B, Payne AM, Dharmaraj S, Bhattacharya SS, Kaplan J, Maumenee IH, Koenekoop R, Birch DG, Heckenlively JR, Daiger SP. Prevalence of AIPL1 mutations in inherited retinal degenerative diseases. Mol Genet Metab, 2000; 70:142-150. PMID: 11139241. PMID: 10873396.
 153. Hoffman DR, Birch EE, Birch DG, Uauy R, Castañeda YS, Lopus MG, Wheaton, DG. Impact of early dietary intake and blood lipid composition of long-chain polyunsaturated fatty acids on later visual development. J Ped Gastroenterol Nutr, 2000; 31:540-553. PMID: 11144440.
 154. Bech-Hansen NT, Naylor MJ, Maybaum TA, Sparkes RL, Koop B, Birch DG, Bergen AA, Prinsen CFM, Polomeno RC, Gal A, Drack AV, Musarella MA, Jacobson SG, Young RSL, Weleber RG. Mutations in the gene for a novel leucine-rich protein, nyctalopin, cause the developmental retinal-circuitry abnormality of X-linked complete congenital stationary night blindness. Nature Genetics, 2000; 26:319-323. PMID: 11062471.
 155. Guevara-Fujita M, Fahrner S, Buraczynska K, Cook J, Wheaton D, Cortes F, Vicencio C, Pena M, Fishman GA, Mintz-Hittner H, Birch DG, Hoffman DR, Mears AJ, Fujita R, Swaroop, A. Five novel *RPGR* mutations in families with X-linked retinitis pigmentosa. Human Mutation, 2000; 396: 1-4.
 156. Birch DG. Focal and multifocal electroretinography. In *Electrophysiologic Testing* (GA Fishman, DG Birch, GE Harding, MG Brignell, editors) American Academy of Ophthalmol, San Francisco, 2001: 177-196.
 157. Mata NL, Tzekov RT, Liu X, Weng J, Birch DG, Travis GH. Delayed dark-adaptation and lipofuscin accumulation in *abcr+/-* mice: Implications for involvement of *ABCR* in age-related macular degeneration. Invest Ophthalmol Vis Sci, 2001; 42:1685-1690. PMID: 11431429.
 158. Sohocki MM, Daiger SP, Bowne SJ, Rodriguez JA, Northrup H, Heckenlively JR, Birch DG, Mintz-Hittner H, Ruiz RS, Lewis RA, Saperstein DA, Sullivan LS. Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies. Hum Mut, 2001; 17:42-51; PMC: 2585061.
 159. Tzekov RT, Liu Y, Sohocki MM, Zack DJ, Daiger SP, Heckenlively JR, Birch DG. Autosomal dominant retinal degeneration and bone loss associated with a 12bp deletion in the CRX gene. Invest Ophthalmol Vis Sci, 2001; 42:1319-1327. PMID: 10756457; PMC: 2581450.

160. Uauy R, Hoffman DR, Peirano P, Birch DG, Birch EE. Essential fatty acids in visual and brain development. Lipids, 2001; 36:885-895. PMID: 11724460.
161. Hoffman DR, DeMar JC, Heird WC, Birch DG, Anderson RE. Impaired synthesis of docosahexaenoic acid (DHA) in patients with x-linked retinitis pigmentosa (XLRP). Journal of Lipid Research, 2001; 42:1395-1401. PMID: 11518758.
162. Berezovsky A, Salomao SR, Birch DG. Pupil size following dark adaptation in patients with retinitis pigmentosa. Brazilian Journal of Medical and Biological Research. 2001; 34:1037-1040. PMID: 11471043.
163. Kedzierski W, Nusinowitz S, Birch DG, Clarke G, McInnes R, Bok D, Travis GH. Deficiency of rds/peripherin causes photoreceptor death in mouse models of digenic and dominant retinitis pigmentosa. Proc Nat Acad Sci, 2001; 98:7718-7723; PMC: 35408.
164. Bowne SJ, Daiger SP, Malone KA, Zuo J, Cheon K, Birch DG, Hughbanks-Wheaton D, Heckenlively JR, Farber DB, Pierce EA, Bhattacharya SS, Inglehearn CF, Sullivan LS. RP1 Mutation Analysis. *New Insights into Retinal Degenerative Diseases* (R. Anderson, J. Hollyfield, and M. LaVail, editors), Kluwer Academic/Plenum, New York, 2001; 55-61.
165. Wheaton DH, Daiger SP, Birch DG. The Southwest Eye Registry, distribution of disease types and mutations. *New Insights into Retinal Degenerative Diseases* (R. Anderson, J. Hollyfield, and M. LaVail, editors), Plenum Publishers, New York, 2001; 339-345.
166. Breuer DK, Affer M, Andreasson S, Birch DG, Fishman GA, Heckenlively JR, Hiriyantha S, Hoffman DR, Jacobson SG, Mears AJ, Mussarella M, Redolfi B, Sieving PA, Wright A, Yashar, Zucchi I, Swaroop A. X-linked retinitis pigmentosa: current status. *New Insights into Retinal Degenerative Diseases* (R. Anderson, J. Hollyfield, and M. LaVail, editors), Kluwer Academic/Plenum, New York, 2001; 11-22.
167. Birch DG, Peters AY, Locke KL, Spencer R, Megarity CF, Travis GH. Visual function in patients with cone-rod dystrophy (CRD) associated with mutations in the *ABCA4* (*ABCR*) gene. Exp Eye Res, 2001; 73:877-886. PMID: 11846518.
168. Birch EE, Hoffman DR, Castañeda Y, Fawcett SL, Birch DG, Uauy R. A randomized controlled trial of long-chain polyunsaturated fatty acid supplementation of formula in term infants after weaning at 6 weeks of age. American Journal of Clinical Nutrition, 2002; 75:570-580. PMID: 11864865.
169. Bowne SJ, Sullivan LS, Blanton SH, Cepko CL, Blackshaw S, Birch DG, Hughbanks-Wheaton D, Heckenlively JR, Daiger SP. Mutations in the inosine monophosphate dehydrogenase 1 gene (*1MPDH1*) cause the RP10 form of autosomal dominant retinitis pigmentosa. Hum Mol Genet, 2002; 11:559-568. PMID: 11875050; PMC: 2585828.
170. Birch DG. Visual adaptation. In *Adler's Physiology of the Eye* (A. Alm and P. Kaufman, editors) Mosby/Saunders, St. Louis, 2002.
171. Birch DG, Toler SM, Swanson W, Fish GE, Laties A. A double-blind, placebo-controlled evaluation of the effects of Sildenafil Citrate (Viagra®) on visual function in subjects with early age-related macular degeneration. American Journal of Ophthalmol, 2002; 133:665-672. PMID: 11992864.
172. Birch DG, Hood DC, Locke KG, Tzekov RT. Quantitative measures of phototransduction in cone and rod photoreceptors: normal aging, progression with disease, and test-retest reliability. Arch Ophthalmol, 2002; 120:1045-1051. PMID: 12149058.
173. Breuer DK, Yashar BM, Filippova E, Hiriyantha S, Lyons R, Asaye B, Acar C, Vervoort R, Wright AF, Musarella M, Wheeler P, MacDonald I, Iannaccone A, Birch DG, Hoffman DR, Fishman GA, Heckenlively JR, Jacobson SG, Sieving PA, Swaroop A. A comprehensive analysis of *RPGR* and *RP2* genes in 233 families with X-linked Retinitis Pigmentosa. American Journal of Human Genetics, 2002; 70:1545-54. PMC: 379141.
174. Grover S, Fishman GA, Birch DG, Locke KG, Rosner B. Variability of full-field electroretinogram responses in subjects without diffuse photoreceptor cell disease. Ophthalmol, 2003; 110:1159-63. PMID: 12799241.
175. Tzekov RT, Locke KG, Hood DC, Birch DG. Cone and rod ERG phototransduction parameters in

- retinitis pigmentosa. Invest Ophthalmol Vis Sci, 2003; 44:3993-4000. PMID: 12939320.
176. Hoffman DR, Birch EE, Castañeda Ys, Fawcett SL, Wheaton DH, Birch DG, Uauy R. Visual function in breast-fed term infants weaned at 4 and 6 months to formula with or without long-chain polyunsaturates: A randomized clinical trial. Journal of Pediatrics, 2003; 142:669-677. PMID: 12838196.
 177. Cideciyan AV, Jacobson SG, Gupta N, Osawa S, Locke KG, Weiss ER, Stone EM, Sheffield VC, Wright AF, Birch DG, Milan AH. Cone deactivation kinetics and GRK1/GRK7 expression in enhanced S cone syndrome caused by mutations in NR2E3. Invest Ophthalmol Vis Sci, 2003; 44:1268-1274. PMID: 12601058.
 178. Wheaton DH, Hoffman DR, Locke KG, Watkins RB, Birch DG. Biological safety assessment of docosahexaenoic acid (DHA) supplementation in a randomized clinical trial for X-linked retinitis pigmentosa. Arch Ophthal, 2003; 121:1269-1278. PMID: 12963609.
 179. Rotenstreich Y, Fishman GA, Anderson, RJ, Birch DG. Interocular amplitude differences of the full-field electroretinogram in normal subjects. British Journal Ophthalmol, 2003; 87:1268-1271. PMID: 14507764; PMC: 1920781.
 180. Bowne SJ, Daiger SP, Malone KA, Heckenlively JR, Kennan A, Humphries P, Hughbanks-Wheaton D, Birch DG, Liu Q, Pierce EA, Zuo J, Huang Q, Sullivan LS. Characterization of RP1L1, a highly polymorphic paralog of the retinitis pigmentosa 1 (RP1) gene. Molecular Vision, 2003; 9:129-37. PMID: 12724644; PMC: 2580755.
 181. Daiger SP, Sullivan LS, Bowne SJ, Kennan A, Humphries P, Birch DG, Heckenlively JR, and the RP1 Consortium. Identification of the RP1 and RP10 (IMPDH1) genes causing autosomal dominant RP. Adv Exp Med Biol, 2003; 533: 1-11. PMID: 15180241; PMC: 2583078.
 182. Kang Derwent JJ, Derlacki DJ, Grover S, Hetling JR, Birch DG, Stone EM, Fishman GA, Pepperberg DR. Dark adaptation of rod photoreceptors in normal subjects and in patients with ABCA4-related Stargardt disease. Invest Ophthalmol Vis Sci, 2004; 45:2447-2456. PMID: 15223829.
 183. Chow RL, Volgyi B, Szilard RK, Ng D, McKerlie C, Bloomfield SA, Birch DG, McInnes, RR. Control of late OFF cone bipolar cell differentiation and visual signaling by the homeobox gene *Vsx1*. Proc Nat Acad Scis, 2004; 101: 1754-1759. PMID: 14745032; PMC: 341848.
 184. Hoffman DR, Locke KG, Wheaton DH, Fish GE, Hillis A, Birch DG. A randomized, placebo-controlled clinical trial of docosahexaenoic acid (DHA) supplementation for X-linked retinitis pigmentosa (XLRP). American Journal of Ophthalmol, 2004; 137: 704-718. PMID: 15059710.
 185. Locke K, Birch DG. Modification of the Kowa RC-2 fundus camera for use with mice. Journal of Ophthalmic Photography, 2004; 26: 81-83.
 186. Birch DG. Surrogate electroretinographic markers for assessing therapeutic efficacy in the retina. Exp Rev Mol Diag, 2004; 4: 693-703. PMID: 15347262.
 187. Dharmaraj S, Leroy BP, Sohocki MM, Koenekoop RK, Perrault I, Anwar K, Khaliq S, Devi RS, Birch DG, De Pool E, Van Maldergem L, Izquierdo N, Ismail M, Payne AM, Holder GE, Bhattacharya SS, Bird AC, Kaplan J, Maumenee IH. The phenotype of Leber congenital amaurosis in patients with AIPL1 mutations. Arch Ophthal, 2004; 122:1029-1037. PMID: 15249368.
 188. Birch EE, Hoffman DR, Castañeda YS, Wheaton DH, Birch DG, Uauy RD. Visual maturation of term infants fed LCP-supplemented or control formula for 12 months. American Journal of Human Nutrition, 2005; 81:871-879. PMID: 15817866.
 189. Fishman GA, Jacobson SG, Alexander KR, Cideciyan A, Birch DG, Weleber R, Hood DC. Outcome measures and their application in clinical trials for retinal degenerative diseases. Retina, 2005; 25:772-777. PMID: 16141867.
 190. Ding K, Scortegagna M, Seaman R, Birch DG, Garcia JA. Retinal pathology in mice lacking the hypoxia-inducible transcription factor HIF-2. Invest Ophthalmol Vis Sci, 2005; 46:1010-1015. PMID: 15728559.
 191. Sullivan LS, Bowne SJ, Shankar SP, Blanton SH, Heckenlively JR, Birch DG, Wheaton DH, Daiger

- SP. Linkage mapping in families with autosomal dominant retinitis pigmentosa (adRP). *Invest Ophthalmol Vis Sci*, 2005; 46(5) 2293-
192. Karan G, Lillo C, Yang Z, Cameron DJ, Locke KL, Zhao Y, Thirumalaichary S, Li C, Birch DG, Williams D, Zhang K. Lipofuscin accumulation, abnormal electrophysiology and photoreceptor degeneration in mutant ELOVL4 transgenic mice: A model for macular degeneration. *Proc Nat Acad Sci*, 2005; 102:4164-4169. PMID: 15749821; PMC: 554798.
 193. Cheng CW, Chow RL, Lebel M, Sakuma R, Cheung HO, Thanabalasingham V, Zhang X, Bruneau BG, Birch DG, McInnes RR, Cheng SH, Hui C. The Iroquois homeobox gene, *Irx*, is required for retinal cone bipolar cell development. *Dev. Biol*, 2005; 287:48-60. PMID: 16214101.
 194. Kasus-Jacobi A, Birch DG, Anderson RE. Photoreceptor retinol dehydrogenases: an attempt to characterize the function of Rdh11. *New Insights into Retinal Degenerative Diseases* (R. Anderson, J. Hollyfield, and M. LaVail, editors), Kluwer Academic/Plenum, New York, 2005.
 195. Kozma P, Hughbanks-Wheaton DK, Locke KG, Fish GE, Bowne SJ, Sullivan LS, Daiger SP, Birch DG. Phenotypic characterization of a large family with RP10 autosomal dominant retinitis pigmentosa: An Asp226Asn mutation in the IMPDH1 gene. *Amer J Ophthalmol*, 2005, 140:858-867. PMID: 16214101; PMC: 2771559.
 196. Kasus-Jacobi A, Ou J, Birch DG, Locke KG, Shelton JM, Richardson JA, Murphy AJ, Valenzuela DM, Yancopoulos GD, Edwards AO. Functional characterization of mRdh11 as a retinol dehydrogenase involved in dark adaptation in vivo. *J Biol Chem*, 2005; 280:20413-20420. PMID: 15790565.
 197. Birch DG. A randomized placebo-controlled clinical trial of docosahexaenoic acid (DHA) supplementation for X-linked retinitis pigmentosa. *Retina*, 2005; 25:S52-S54. PMID: 16374336.
 198. McGee J, Goodyear RJ, McMillan DR, Holt J, Locke KG, Birch DG, Legani PK, White PC, Walsh E, Richardson GP. The very large G-protein coupled receptor, *vlg1*, a component of the ankle link complex required for the normal development of the auditory hair bundles. *J Neurosci*, 2006; 26:6543-6553. PMID: 16775142; PMC: 2682555.
 199. Bowne SJ, Sullivan LS, Mortimer SE, Hedstrom L, Zhu J, Spellicy CJ, Gire AI, Hughbanks-Wheaton D, Birch DG, Lewis RA, Heckenlively JR, Daiger SP. Spectrum and frequency of mutations in IMPDH1 associated dominant retinitis pigmentosa and Leber congenital amaurosis. *Invest Ophthalmol Vis Sci*, 2006, 47:34-42. PMID: 16384941; PMC: 2581444.
 200. Hood DC, Birch DG. Measuring the health of the human photoreceptors with the leading edge of the a-wave. In Heckenlively, J. and Arden, G. (Eds.) *Principles and Practice of Clinical Electroretinography of Vision, 2nd Edition*. MIT Press, Cambridge, MA. 2006: 487-502.
 201. Birch DG. Stargardt disease. In Heckenlively, J. and Arden, G. (Eds.) *Principles and Practice of Clinical Electroretinography of Vision, 2nd Edition*. MIT Press, Cambridge, MA. 2006: 727-734.
 202. Birch DG. Retinitis pigmentosa. In Heckenlively, J. and Arden, G. (Eds.) *Principles and Practice of Clinical Electroretinography of Vision, 2nd Edition*. MIT Press, Cambridge, MA. 2006: 781-794.
 203. Birch DG. Diseases of Fatty Acid Storage and Metabolism: Neuronal Ceroid Lipofuscinoses and the Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency. In Heckenlively, J. and Arden, G. (Eds.) *Principles and Practice of Clinical Electroretinography of Vision, 2nd Edition*. MIT Press, Cambridge, MA. 2006: 889-896.
 204. Sullivan LS, Bowne SJ, Birch DG, Wheaton D, Heckenlively JR, Lewis RA, Garcia CA, Ruiz RS, Blanton SH, Gire AI, Seaman R, Duzkale H, Spellicy CJ, Zhu J, Shankar SP, Daiger SP. Prevalence of disease-causing mutations in families with autosomal dominant retinitis pigmentosa (adRP): A screen of known genes in a cohort of 200 families. *Invest Ophthalmol Vis Sci*, 2006; 47:3052-64. PMID:16799052 PMCID:PMC2585061
 205. Kasus-Jacobi A, Birch, DG, Anderson RE. Photoreceptor retinol dehydrogenases. An attempt to characterize the function of Rdh11. *Adv Exp Med Biol*, 2006; 575:505-11. PMID: 17249616.
 206. Sullivan LS, Bowne SJ, Seaman CR, Blanton SH, Lewis, RA, Heckenlively JR, Birch DG, Wheaton D, Daiger SP. Genomic rearrangements of the PRPF31 gene account for 2.5% of autosomal

- dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci, 2006; 47:4579-88. PMID: 16799052; PMC: 2778205
207. Kozma P, Wang Y-Z, Birch DG, Edwards AO. Persistent cone dysfunction in acute exudative polymorphous vitelliform maculopathy. Retina, 2007; 27:109-112. PMID: 17218926.
208. McMahon A, Butovich I, Mata NL, Klein M, Ritter R, Richardson J, Birch DG, Edwards AO, Kedzierski W. Retinal pathology and skin barrier defect in mice carrying a Stargardt-3 mutation in elongase of very long chain fatty acids-4. Mol Vis, 2007; 13:258-72. PMID: 17356513; PMC: 2633486.
209. Birch DG, Liang FQ. Age-related macular degeneration: A target for nano-technology derived medicines. International J Nanomedicine, 2007; 2:1-13. PMID: 17722514.
210. Gire AI, Sullivan LS, Bowne SJ, Birch DG, Hughbanks-Wheaton D, Heckenlively JR, Daiger SP. The Gly56Arg mutation in NR2E3 accounts for 1-2% of autosomal dominant retinitis pigmentosa. Molecular Vision, 2007; 13:1970-5. PMID: 17982421; PMC: 2673815.
211. Yang Z, Chen Y, Lillo C, Chien J, Yu Z, Michaelides M, Klein M, Howes KA, Li Y, Kaminoh Y, Chen H, Zhao C, Chen Y, Al-Sheikh Y, Karan G, Corbeil D, Escher P, Kamaya S, Li C, Johnson S, Frederick JM, Zhao Y, Wang C, Cameron D, Huttner W, Schorderet D, Munier F, Moore A, Birch DG, Baehr W, Hunt DM, Williams DS, Zhang K. Mutant prominin 1 found in patients with macular degeneration disrupts photoreceptor disk morphogenesis in mice. J Clinical Investigation, 2008; 118:2908-16. PMID: 18654668; PMC 2483685.
212. Daiger SP, Sullivan LS, Gire AI, Birch DG, Heckenlively JR, Bowne SJ. Mutations in known genes account for 58% of autosomal dominant retinitis pigmentosa (adRP). Adv Exp Med Biol, 2008; 613:203-9. PMID: 18188946; PMC: 2582019.
213. Bowne SJ, Sullivan LS, Gire AI, Birch DG, Hughbanks-Wheaton D, Heckenlively JR, Daiger SP. Mutations in the TOPORS gene cause 1% of autosomal dominant retinitis pigmentosa (adRP). Mol Vis, 2008; 14:922-7. PMID: 18509552; PMC: 2391085.
214. Jiang L, Wheaton D, Bereta G, Zhang K, Palczewski K, Birch D, Baehr W. A novel GCAP1 (N104K) mutation in EF hand 3 (EF3) linked to autosomal dominant cone dystrophy. Vision Res, 2008 48:2425-32. [Epub 2008 Sep 16]. PubMed PMID:18706439.
215. Kitiratschky VB, Wilke R, Renner AB, Kellner U, Vadalà M, Birch DG, Wissinger B, Zrenner E, Kohl S. Mutation analysis identifies GUCY2D as the major gene responsible for autosomal dominant progressive cone degeneration. Invest Ophthalmol Vis Sci, 2008; 11:5015-23. [Epub 2008 May 16]. PMID 18487367.
216. Hood DC, Lin CE, Lazow MA, Locke KG, Zhang X, Birch DG. Thickness of receptor and post-receptor retinal layers in patients with retinitis pigmentosa measured with frequency-domain optical coherence tomography. Invest Ophthalmol Vis Sci, 2009: 2328-36 [Epub 2008 Nov 14]. PMID: 19011017, PMCID: PMC2835526.
217. Friedman JS, Ray JW, Waseem N, Johnson K, Brooks MJ, Hugosson T, Breuer D, Branham KE, Krauth DS, Bowne SJ, Sullivan LS, Ponjavic V, Gränse L, Khanna R, Trager EH, Gieser LM, Hughbanks-Wheaton D, Cojocarui RI, Ghiasvand NM, Chakarova CF, Abrahamson M, Göring HH, Webster AR, Birch DG, Abecasis GR, Fann Y, Bhattacharya SS, Daiger SP, Heckenlively JR, Andréasson S, Swaroop A. Mutations in a BTB-Kelch protein, KLHL7, cause autosomal-dominant retinitis pigmentosa. Am J Hum Genet, 2009; 84:792-800. PMID: 19520207; PMCID: PMC2694974.
218. Klein M, Birch DG. Psychophysical assessment of low vision function in patients with retinal degenerative diseases (RDDs) with the Diagnosys full-field stimulus threshold (D-FST). Doc Ophthalmol, 2009; 119(3) 217-24. Nov 3. [Epub ahead of print] PMID: 19885692. PMCID:PMC3519829
219. Cordell WH, Maturi RK, Costigan TM, Marmor MF, Weleber RG, Coupland SG, Danis RP, McGettigan JW Jr, Antoszyk AN, Klise S, Sides GD, Adams N, Altaweel MM, Auerbach SM, Bearely S, Birch DG, Cochran JS, Conway MD, Costabile RA, Creel DJ, Donatucci CF, Finkelstein

- D, Fish GE, Garber FW, Harris AE, Maggiano JM, Newman SA, Nussdorf JD, Palace EM, Patel BJ, Rood RS, Rosa RH, Singerman LJ, Teske MP, Ver Hoeve JN, Weiser DC, Young JM, Zegarra H. Retinal effects of 6 months of daily use of tadalafil or sildenafil. Arch Ophthalmol, 2009; 127: 367-73. PMID: 19365010.
220. Birch DG, Williams PD, Callanan D, Wang R, Locke KG, Hood DC. Macular atrophy in birdshot retinochoroidopathy: An optical coherence tomography and multifocal electroretinography analysis. Retina, 2010; 30: 930-7. PMID: 20098346, PMCID: PMC2884075
 221. Rangaswamy NV, Patel HM, Locke KG, Hood DC, Birch DG. A comparison of visual field sensitivity to photoreceptor thickness in retinitis pigmentosa. Invest Ophthalmol Vis Sci, 2010; 51:4213-4219. PMID: 20220048 PMCID:PMC2910646.
 222. Daiger SP, Sullivan LS, Bowne SJ, Birch DG, Heckenlively JR, Pierce EA, Weinstock GM. Targeted high-throughput DNA sequencing for gene discovery in retinitis pigmentosa. Adv Exp Med Biol, 2010; 664: 325-331. PMID: 20238032.
 223. Locke KG, Wheaton D, Bowne SJ, Sullivan LS, Coors L, Birch DG. Optical coherence tomography in patients diagnosed with North Carolina Macular Dystrophy. J Ophthal Photog, 2010; 32:64-71.
 224. Birch DG, Birch EE, Spencer R. Electroretinographic testing in infants and children. In Reynolds JD and Olitsky SE (Eds) Pediatric Retina, Springer, Heidelberg, 2010:67-84.
 225. Sullivan JM, Birch DG, Spencer R. Pediatric Hereditary Macular Degenerations. In Reynolds JD and Olitsky SE (Eds) Pediatric Retina, Springer, Heidelberg, 2010:245-294.
 226. Hood DC, Lazow MA, Locke KG, Greenstein VC, Birch DG. The transition zone between healthy and diseased retina in patients with retinitis pigmentosa (RP). Invest Ophthalmol Vis Sci, 2011; 52: 101-108. Aug 20 [Epub ahead of print] PMID: 20720228, PMCID: PMC3053270.
 227. Wen YE, Locke KG, Hood DC, Birch DG. Rod photoreceptor temporal properties in retinitis pigmentosa. Exp Eye Res, 2011; Mar;92(3):202-8. Epub 2011 Jan 8. PMID: 21219898, PMCID: PMC4145877.
 228. Bowne SJ, Sullivan LS, Koboldt DC, Ding L, Fulton R, Abbott RM, Sodergren EJ, Birch DG, Wheaton DH, Heckenlively JR, Qin L, Pierce EA, Weinstock GM, Daiger SP. Identification of disease-causing mutations in autosomal dominant retinitis pigmentosa (adRP) using next-generation DNA sequencing. Invest Ophthalmol Vis Sci, 2011; 52:494-503. Sept 24, 2010 [Epub ahead of print] PMID: 20861475, PMCID:PMC3053293.
 229. Zhang K, Hopkins J, Heier J, Birch D, Halperin L, Albin T, Brown D, Jaffe G, Tao W, Williams G. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci USA, 2011, Apr 12; 108(15): 6241-5. Epub 2011 Mar 28. PMID: 2144807, PMCID: PMC3076847.
 230. Birch DG, Wen Y, Locke KI, Hood DC. Rod sensitivity, cone sensitivity and photoreceptor layer thickness in retinal degenerative diseases. Invest Ophthalmol Vis Sci, 2011; 52(10): 7141-7. Sept 9, 2011 [Epub ahead of print] PMID: 21810977.
 231. Wen Y, Locke KG, Klein M, Bowne SJ, Sullivan LS, Ray JW, Daiger SP, Birch DG, Hughbanks-Wheaton DK. Phenotypic characterization of 3 families with autosomal dominant retinitis pigmentosa (adRP) due to mutations in KLHL7. Arch Ophthalmol, 2011 Nov; 129(11): 1475-82. PMID: 22084217.
 232. Hood DC, Ramachandran R, Holopigian K, Lazow M, Birch DG, Greenstein VC. Method for deriving visual field boundaries from OCT scans of patients with retinitis pigmentosa. Biomed Opt Express, 2011 Apr 5:2(5): 10106-14. PMID: 21559123.
 233. Fahim AT, Bowne SJ, Sullivan LS, Clark K, Williams JT, Wheaton DK, Birch DG, Daiger SP. Allelic heterogeneity and genetic modifier loci contribute to clinical variation in males with X-linked retinitis pigmentosa due to mutations in RPGR. PLoS One, 2011; 6(8): e23021. Epub 2011 Aug 12. PMID: 21857984.
 234. Trotter JH, Klein M, Jinwal U, Abisambra J, Dickey C, Tharkur J, Masiulis I, Ding JD, Locke KG, Bowes-Rickman C, Birch DG, Weeber EJ, Herz J. ApoER2 function in the establishment and

- maintenance of retinal synaptic connectivity. J Neurosci, 2011 Oct 5; 31(40): 14413-23. PMID: 21976526, PMCID: PMC3224795.
235. Lazow MA, Hood DC, Ramachandran R, Burke TR, Wang Yi-Z, Greenstein VC, Birch DG. Transition zones between healthy and diseased retina in choroideremia (CHM) and Stargardt disease (STGD) as compared to retinitis pigmentosa (RP). Invest Ophthalmol Vis Sci, 2011; 52(13): 9581-9590 Nov 9, 2011 [Epub ahead of print] PMID: 22076985.
 236. Hood DC, Zhang X, Ramachandran R, Talamini CL, Raza A, Greenberg JP, Sherman J, Tsang SH, Birch DG. The inner segment/outer segment border seen on optical coherence tomography is less intense in patients with diminished cone function. Invest Ophthalmol Vis Sci, 2011; 52(13): 9703-9709 Nov 22, 2011 [Epub ahead of print] PMID: 22110066.
 237. Duncan JL, Ratnam K, Birch DG, Sundquist SM, Lucero AS, Zhang Y, Meltzer M, Smaoui N, Roorda A. Abnormal cone structure in foveal schisis cavities in X-linked retinoschisis (XLRs) from mutations in exon 6 of the RS1 gene. Invest Ophthalmol Vis Sci, 2011; 52(13): 9614-9623 Nov 22 [Epub ahead of print]. PMID: 22110067.
 238. Kubota R, Boman NL, David R, Mallikaajun S, Patil S, Birch DG. The safety and effect on rod function of ACU-4429, a novel small-molecule visual cycle modulator. Retina, 2012; 32(1):183-8. Apr 21, 2011 [Epub ahead of print] PMID: 21519291.
 239. Humayun MS, Dorn JD, daCruz L, Dagnelie G, Sahel JA, Stanga PE, Cideciyan AV, Duncan JL, Elliott D, Filley, E, Birch DG, Ho AC, Santos A, Safran AB, Arditi A, Del Priore LV, Greenberg R. Interim results from the international trial of Second Sight's prosthesis. Ophthalmology, 2012 Jan 11 [Epub ahead of print].
 240. Fahim AT, Bowne SJ, Sullivan LS, Clark K, Williams JT, Wheaton DK, Birch DG, Daiger SP. Polymorphic variation of RPGRIP1L and IQCB1 as modifiers of X-linked retinitis pigmentosa caused by mutations in RPGR. Advances in Experimental Medicine & Biology, 2012; 723(5): 313-320. PMID: 22183348.
 241. Peachey NS, Ray TA, Florijn R, Rowe LB, Trijntje S, Contreras-Alcantare S, Baba K, Tosini G, Pozdeyev N, Iuvone PM, Bojang P, Pearring JN, Simonsz HJ, van Genderen M, Birch DG, Traboulsi EI, Dorfman A, Lopez I, Ren H, Goldberg AF, Nishina PM, Lachapelle P, McCall MA, Koenekoop RC, Bergen AA, Kamermans M, Gregg RG. GPR179 is required for depolarizing bipolar cell function and is mutated in autosomal recessive complete stationary night blindness. American Journal of Human Genetics, 2012; 90(2): 331-339. PMID: 22325362.
 242. Wen YE, Locke KG, Hood DC, Birch DG. Rod photoreceptor temporal properties in retinal degenerative diseases. Advances in Experimental Medicine & Biology, 2012; 723(5): 495-502. PMID: 22183369. PMCID: PMC4145877.
 243. Wen YE, Klein M, Hood DC, Birch DG. Relationships among multifocal electroretinogram amplitude, visual field sensitivity, and SD-OCT receptor layer thickness in patients with retinitis pigmentosa. Invest Ophthalmol Vis Sci, 2012; 53(2):833-840 Jan 12, 2012 [Epub ahead of print]. PMID: 22247460.
 244. Li X, McClennan ME, Tanito M, Gartesier P, Towner R, Bissig D, Berkowitz BA, Fliesler SJ, Woodruff ML, Fain GL, Birch DG, Khan S, Ash JD, Elliott MH. Loss of caveolin-1 impairs retinal function due to a disturbance of the subretinal microenvironment. J Biol Chem, 2012; 287(20):16424-16434. PMID: 22451674.
 245. Chen CJ, Scholl HPN, Birch DG, Iwata T, Miller N, Goldberg MF. Characterizing the phenotype and genotype of a family with occult macular dystrophy. Arch Ophthalmol, 2012 130(12):1554-9. PMID: 23229695, PMCID: PMC4114073.
 246. Branham K, Othman M, Brumm MV, Karoukis AJ, Atmaca-Sonmez P, Yashar B, Schwartz, SB, Stover, NB, Truzpek K, Wheaton D, Jennings B, Ciccarelli M, Jayasundera KT, Lewis R, Birch DG, Bennett J, Sieving P, Andreasson S, Duncan J, Fishman G, Iannaccone A, Weleber RG, Jacobson SG, Heckenlively JR, and Swaroop A. Mutations in *RPGR* and *RP2* account for 15% of males with simplex retinal degenerative diseases. Invest Ophthalmol Vis Sci, 2012, 53:8232-8237. PMID:

23150612.

247. Yanni SE, Wang J, Patel CS, Locke KI, Wen Y, Birch DG, Birch EE. Normative reference ranges for the retinal nerve fiber layer, macula, and retinal layer thicknesses in children. Amer J Ophthalmol. 2013; 155(2):354-60. PMID: 23127751, PMCID: PMC3545013.
248. Churchill JD, Bowne SJ, Sullivan LS, Lewis RA, Wheaton DK, Birch DG, Branham KE, Heckenlively JR, Daiger SP. Mutations in the X-linked retinitis pigmentosa genes *RPGR* and *RP2* found in 8.5% of families with a provisional diagnosis of autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci, 2013, 54:1411-1416. PMID: 23372056.
249. Birch DG, Locke KG, Wen Y, Locke KI, Hoffman DR, Hood DC. Spectral-domain optical coherence tomography measures of outer segment layer progression in patients with x-linked retinitis pigmentosa. JAMA Ophthalmol, 2013, 131(9): 1143-1150. July 4. PMID: 23828615 PMCID: PMC4111937.
250. Wang X, Wang H, Sun V, Wang K, Keser V, Tuan H-F, Ren H, Lopez I, Zaneveld E, Siddiqui S, Bowles S, Khan A, Wang F, Fishman G, Salvo S, Birch D, Heckenlively J, Jacobson S, Traboulsi E, Koenekoop R, Chen R. Comprehensive molecular diagnosis of 179 Leber congenital amaurosis and juvenile retinitis pigmentosa patients by targeted next-generation sequencing. Journal of Medical Genetics, 2013, 0:1-15. July 11 (Epub ahead of print). PMID: 23847139.
251. Mata NL, Kubota R, Schneider S, Kiisner J, Birch DG. Pharmacodynamics of visual cycle modulation in the treatment of geographic atrophy. Retinal Physician, 2013, Sept 1.
252. Wang F, Wang H, Tuan H-F, Nguyen D, Sun V, Bowne AJ, Rauscher K, Luo H, Wang X, Zaneveld JE, Salvo JS, Sullivan LS, Saddiqui S, Mao L, Wheaton DK, Birch DG, Brenham KE, Heckenlively JR, Ferreyre H, Khan A, Ren H, Keser V, Wang K, Lopez I, Quamr R, Solanki N, Zenteno JC, Ayala R, Fu Q, Simpson DA, Li Y, Sui R, Silvestri G, Daiger SP, Koenekoop R, Zhang K, Chen R. Next generation sequencing-based molecular diagnosis of retinitis pigmentosa: Genetic studies leading to the identification of novel genotype-phenotype correlations and clinical re-classifications. Hum Genet. 2014, Mar; 133(3): 331-45. PMID: 241546662.
253. Birch DG, Weleber RG, Duncan J, Jaffe GL, Tao W, Ciliary Neurotrophic Factor Retinitis Pigmentosa Study Groups. Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa. Amer J Ophthalmol, 2013, 156(2): 283-292. May 10 (Epub ahead of print). PMID: 23668681, PMCID: PMC4111936.
254. Bowne SJ, Sullivan LS, Avery CE, Sasser EM, Wheaton DH, Birch DG, Branham KE, Heckenlively JR, Sieving PA, Daiger SP. Mutations in the SNRNP200 gene cause 1.6% of autosomal dominant retinitis pigmentosa. Mol Vis. 2013, 19:2407-17. PMID: 24319334.
255. Ramachandran R, Zhou L, Locke KG, Birch DG, Hood DC. A comparison of methods for tracking progression in X-linked retinitis pigmentosa using frequency domain OCT. Translational Vision Science & Technology, 2013, 2(7): 1-9. Epub 2013 Nov 11. PMID: 24349883.
256. Hoffman DR, Hughbanks-Wheaton DK, Pearson SN, Fish GE, Spencer R, Takacs A, Klein M, Locke KG, Birch DG. Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial) A randomized clinical trial. JAMA Ophthalmology, 2014 Jul 1;132(7):866-73. PMID: 24805262.
257. Hughbanks-Wheaton DK, Birch DG, Fish GE, Spencer R, Pearson NS, Takacs A, Hoffman DR. Safety assessment of docosahexaenoic acid (DHA) supplementation in a 4-year randomized clinical trial in X-linked retinitis pigmentosa (XLRP). Invest Ophthalmol Vis Sci, 2014 Jul 11; IOVS-14-14437 [Epub ahead of print] PMID: 25015354.
258. Sullivan L, Bowne S, Blanton S, Cadena E, Avery C, Wheaton D, Garcia, C, Fulton R, Wilson R, Weinstock G, Birch D, Lewis R, Daiger S. A dominant mutation in hexokinase 1 (HK1) causes retinitis pigmentosa. Invest Ophthalmol Vis Sci, 2014;55:7147-7158. PMID: 25190649
259. Cai CX, Locke KG, Ramachandran R, Birch DG, Hood DC. A comparison of progressive loss of the ellipsoid zone (EZ) band in autosomal dominant and x-linked retinitis pigmentosa. Invest Ophthalmol Vis Sci, 2014, Epub 2014 October 23, 14-15013. PMID: 25342618

260. Birch DG, Fizke F, Rubin G. Evaluating Visual Function, Endpoints in Lasker/IRRF Initiative for Innovation in Vision Science (ed Dowling, J) *Translational Vision Science & Technology*, 2014, 3: 63-69.
261. Shankar SP, Birch DG, Ruiz RS, Sullivan LS, Bowne SJ, Stone EM, Daiger SP. Founder effect of a c.828+3A>T splice site mutation in *Peripherin2* (*PRPH2*) causing autosomal dominant retinal dystrophies. *JAMA Ophthalmology*, 2015 May: 133(5):511-517. Epub 2015 February 12. PMID:PMC4449732.
262. Birch DG, Locke KG, Felius J, Klein M, Wheaton KH, Hoffman DR, Hood DC. Rates of decline in fdOCT-defined regions of the visual field in patients with RPGR-mediated X-linked retinitis pigmentosa (XLRP). *Ophthalmology* 2015, 122(4):833-9. PMID: PMC4372456.
263. Ho AC, Humayun MS, Dorn JD, Da Cruz L, Dagnelie G, Handa J, Barale PO, Sahel J-A, Stanga PE, Hafezi F, Safran A, Salzman J, Santos A, Birch DG, Spencer R, Cideciyan AV, de Juan E, Duncan JL, Elliott D, Fawzi A, Olmos de Koo LC, Brown G, Haller J, Regillo C, Del Priore LC, Arditi A, Geruschat DR, Greenberg RJ. Long-term results from an epiretinal prosthesis to restore sight to the blind. *Ophthalmology*. 2015, 122(8):1547-1554.
264. Dugel PU, Novack RL, Czaky KG, Richmond PP, Birch DG, Kubota R. Phase II, randomized, placebo-controlled, 90-day study of Emixustat HCL in geographic atrophy associated with dry age-related macular degeneration. *Retina*, 2015 Jun;35(6):1173-83 Apr 29 [Epub ahead of print]. PMID: PMC4452434.
265. Batabyal S, Cervenka G, Birch D, Kim Y-T, Mohanty S. Broadband activation by white-opsin lowers intensity threshold for cellular stimulation. *Nature Scientific Reports* 2015 Epub 14 Dec 2015.
266. Jung CC, Atan D, Ng D, Ploder L, Ross S, Klein M, Birch DG, Diez E, McInnes RR. The transcription factor *PRDM8* is required for rod bipolar and type 2 OFF-cone bipolar cell survival and amacrine subtype identity. *Proc Natl Acad Sci USA*, 2015 Jun 9; 112(23):E3010-9. Epub 2015 May 28. PMID: 26023183
267. Scholl HPN, Moore AT, Koenekoop RK, Wen Y, Fishman GA, van der Born LI, Bittner A, Bowles K, Fletcher EC, Collison FT, Dagnelie G, Eposti SD, Michaelides M, Saperstein DA, Schuchard RA, Zein W, Zobor D, Birch DG, Mendola JD, Zrenner E. Safety and proof-of-concept study of oral QLT09001 in retinitis pigmentosa due to inherited deficiencies of retinal pigment epithelial 65 protein (*RPE65*) or *Lecithin:Retinol acyltransferase* (*LRAT*). *PloS One*. 2015 10; 10(12). PMID: 26656277
268. Wen YE, Birch DG. Outer segment thickness measured by SD-OCT in the macula may predict Goldmann visual field response to QLT091001 in patients with LCA or RP associated with *RPE65* or *LRAD* mutations. *Transl Vis Sci & Tech*. 2015, 4(5), 1-10. PMID: 26448901
269. Hoffman DR, Hughbanks-Wheaton DK, Spencer R, Fish GE, Pearson NS, Wang Y-Z, Klein M, Takacs A, Locke KG, Birch DG. Docosahexaenoic acid slows visual field progression in x-linked retinitis pigmentosa: Ancillary outcomes of the DHAX trial. *Investigative Ophthalmology and Visual Science*. 2015, 56 (11), 6646-6653. PMID: 26469750
270. Shankar SP, Wheaton DK, Birch DG, Sullivan LS, Conneely KN, Bowne SJ, Stone EM, Daiger SP. Autosomal dominant retinal dystrophies caused by a founder splice site mutation, c.828+3A>T, in *PRPH2* and protein haplotypes *in trans* as modifiers. *Invest Ophthalmol Vis Sci.*, 2016, 57(2): 349-59. PMID: 26842753
271. Carr C, Emigh CE, Bennett LD, Pansick AD, Birch DG, Nguyen C. Towards a treatment for diabetic retinopathy: Intravitreal toxicity and preclinical safety evaluation of inducible nitric oxide synthase inhibitors. *Retina*. 2017 Jan;37(1):22-31. doi: 10.1097/IAE.0000000000001133. PMID:27380429
272. Ghazi NG, Abboud EB, Nowilaty SR, Alkuraya H, Alhommadi A, Cai H, Hou R, Deng W, Boye SL, Alhommadi A, Al Saikhan F, Al-Dhibi H, Birch DG, Chung C, Colak S, LaVail MM, Vollrath D, Erger K, Wang W, Conlon T, Zhang K, Hauswirth W, Alkuraya F. *MERTK* gene therapy for patients with *MERTK*-related retinitis pigmentosa. *Hum Genet*. 2016, 135:327-343.
273. Sadda S, Chakravarthy U, Birch DG, Staurengi EH, Henry E, Brittain C. Clinical endpoints for the

- study of geographic atrophy secondary to AMD. *Retina*; 2016, 10:1806-22. PMID:27652913
PMCID: In Process
274. Buena-Atienza E, Rütther K, Baumann B, Bergholz R, Birch DG, De Baere E, Dollfus H, Grealley MT, Gustavsson P, Hamel CP, Heckenlively JR, Leroy BP, Plomp AS, Pott JW, Rose K, Rosenberg T, Stark Z, Verhrij JBG, Weleber R, Zobor D, Weisschuh N, Kohl S, Wissinger B. De novo intrachromosomal gene conversion from OPN1MW to OPN1LW in the male germline results in Blue Cone Monochromacy. *Nature/Scientific Reports* 2016, DOI:10.1038.
 275. Weisschuh N, Mayer AK, Strom TM, Glöckle N, Schubach M, Andreasson S, Bernd A, Birch DG, Hamel CP, Heckenlively JR, Jacobson SG, Kellner U, Kunstmann E, Maffei P, Poloschek C, Rohrschneider K, Rosenberg T, Rudolph G, Varsányi D, Weleber RG, Wissinger B. Mutation detection in patients with retinal dystrophies using targeted next generation sequencing. *PloS One*. 2016 Jan 14; 11(1). PMID: 26766544
 276. Daiger SP, Sullivan LS, Bowne SJ, Koboldt DC, Blanton SH, Wheaton DK, Avery CE, Cadena ED, Koenekoop RK, Fulton RS, Wilson RK, Weinstock GM, Lewis RA, Birch DG. Identification of a novel gene on 10q22.1 causing autosomal dominant retinitis pigmentosa (adRP). *Adv Exp Med Biol* 2016; 854: 193-200. PMID: 26427411 PMCID: PMC4906966
 277. Strauss RW, Ho A, Munoz B, Cideciyan A, Sahal J, Sunness J, Birch DG, Bernstein PS, Michaelides M, Traboulsi E, Zrenner E, Sadda S, Ervin A, West S, Scholl HPN for the Progression of Stargardt Disease Study Group. The natural history of the progression of atrophy secondary Stargardt disease (ProgStar). Design and baseline characteristics (ProgStar Report # 1). *Ophthalmology*, 2016; 15: 1433-5. PMID: 26786511
 278. Bennett LD, Wang YZ, Klein M, Pennesi ME, Jayasundera T, Birch DG. Structure/psychophysical relationships in X-linked retinoschisis. *Invest Ophthalmol Vis Sci*. 2016; 57: 332-337. PMID: 26830370
 279. Smith TB, Parker M, Steinkamp PN, Weleber RG, Smith N, Wilson DJ; VPA Clinical Trial Study Group; EZ Working Group. Structure-function modeling of OCT and standard automated perimetry in autosomal dominant retinitis pigmentosa. *PLoS One* 2016; Feb 4; 11(2). PMID: 26845445 PMCID: PMC4741516
 280. Hariri AH, Zhang HY, Ho A, Francis P, Weleber RG, Birch DG, Ferris FL, Sadda SR; Trial of Oral Valproic Acid for Retinitis Pigmentosa Group. A novel method for tracking progression in retinitis pigmentosa: quantifying ellipsoid zone area on *En Face* OCT images. *JAMA Ophthalmol*. 2016; 134(6): 628-35. PMID: 27031504 PMCID: PMC27031504
 281. Ghodasra DH, Chen A, Arevalo JF, Birch DG, Branham K, Coley B, Dagnelie G, deJuan E, Devenyi RG, Dorn JD, Fisher A, Geruschat DR, Gregori NZ, Greenberg RJ, Hahn P, Ho A, Howson A, Huang SS, Iezzi R, Khan N, Lam BL, Lim JI, Locke K, Markowitz M, Ripley A-M, Rankin M, Schimitzek H, Tripp F, Weiland JD, Yan J, Zacks DN, Jayasundera KT. Worldwide Argus II implementation: recommendations to optimize patient outcomes. *BMC Ophthalmol* 2016; 16(1):129. PMID: 27154461
 282. Birch DG, Bennett LD, Duncan JL, Pennesi ME. Long-term follow-up of patients with retinitis pigmentosa (RP) receiving sustained-release ciliary neurotrophic factor through intraocular encapsulated cell technology implants. *Am J Ophthalmol*. 2016; 170:10-14. PMID: 27457255 PMCID: PMC5056139
 283. Ramachandran R, Cai C, Lee D, Epstein B, Locke KG, Birch DG, Hood DC. Reliability of a manual procedure for marking the EZ band endpoint location. *Transl Vis Sci & Tech*. 2016; 5(3): 1-10. PMID: 27226930 PMCID: PMC4874452
 284. da Cruz L, Dorn JD, Dagnelie G, Handa J, Barale P, Sahel J, Stanga PE, Hafezi F, Safran AB, Salzmann J, Santos A, Birch DG, Spencer R, Cideciyan AV, deJuan E, Duncan JL, Elliott D, Fawzi A, Humayun MS, Olmos de Koo LC, Ho AC, Brown G, Haller J, Regillo C, Del Priore L, Arditi A, Greenberg RJ, for the Argus II Study Group. Five-year safety and performance results from the Argus II retinal prosthesis system clinical trial. *Ophthalmology* 2016 Oct;123(10):2248-54. PMID:

- 27453256.
285. Ventura MJ, Wheaton D, Xu M, Birch DG, Bowne S, Sullivan L, Daiger S, Jones R, Moser AB, Chen R, Wangler MF. Diagnosis of a mild peroxisomal phenotype with next-generation sequencing. *Molecular Genetics and Metabolism. Mol Genet Metab Rep.* 2016 9:75-78. PMID: 27872819. PMCID: PMC5109284
 286. Bowne SJ, Sullivan LS, Wheaton DK, Locke KG, Jones KD, Kobaltd DC, Fulton BS, Birch DG, Daiger SP. North Carolina Macular Dystrophy (MCDR1) caused by a novel tandem duplication of the *PRDM13* gene. *Molecular Vision* 2016; 22:1239-1247. PMID:27777503
 287. Nittala MG, Velega SB, Hariri A, Birch DG, Haines J, Pericak-Vance MA, Stambolian D, Sadda SR. Scotopic and mesopic retinal sensitivity in age-related macular degeneration in an Amish population. *Retina.* In Press.
 288. Strauss RW, Muñoz B, Ho A, Jha A, Michaelides M, Cideciyan AV, Audo I, Birch DG, Hariri AH, Nittala MG, Sadda S, West S, Scholl HPN. Progression of Stargardt disease as determined by fundus autofluorescence in the retrospective progression of Stargardt disease study (*ProgStar Report No. 9*). *JAMA Ophthalmol.* 2017 Nov 1;135(11):1232-1241. doi:10.1001/jamaophthalmol.2017.4152. PMID:29049437
 289. Radziwon A, Arno G, Wheaton DK, McDonagh EM, Baple EL, Jones KD, Birch DG, Webster AR, MacDonald I. Single base pair substitution in the *CHM* promoter as a cause of choroideremia. *Hum Mutat.* 2017 Jun;38(6):704-715. doi: 10.1002/humu.23212. Epub 2017 Mar 24. PMID:28271586
 290. Schönbach EM, Wolfson Y, Strauss RW, Ibrahim MA, Kong X, Muñoz B, Birch DG, Cideciyan AV, Hahn GA, Sunness JS, Sadda SR, West SK, Scholl HP for the ProgStar Study Group. Macular sensitivity measured with microperimetry in progression of Stargardt disease study: ProgStar report #7. *JAMA Ophthalmol.* 2017 Jul 1;135(7):696-703. doi: 10.1001/jamaophthalmol.2017.1162. PMID:28542693
 291. Sullivan LS, Bowne SJ, Kobolt DC, Cadena EL, Heckenlively JR, Branham KE, Birch DG, Wheaton DH, Jones KD, Ruiz RS, Pennesi M, Northrup H, Gurevich VV, Xu M, Li Y, Chen R, Daiger SP. A novel dominant mutation in *SAG*, the arrestin-1 gene, is a common cause of retinitis pigmentosa in Hispanic families in the southwestern United States. *Invest Ophthalmol Vis Sci.* 2017 May 1;58(5):2774-2784. doi: 10.1167/iovs.16-21341. PMID:28549094
 292. Strauss RW, Muñoz B, Ho A, Jha A, Sahel J-A, Cideciyan AV, Birch DG, Sadda S, West S, Scholl HPN. The incidence of atrophic lesions in Stargardt disease in the progression of atrophy secondary to Stargardt disease study (ProgStar) study: Progstar report #5. *JAMA Ophthalmol.* 2017 Jul 1;135(7):687-695. doi: 10.1001/jamaophthalmol.2017.1121. PMID:28542697
 293. Daiger SP, Bowne SJ, Sullivan LS, Branham K, Wheaton DK, Jones KD, Avery CE, Cadena ED, Heckenlively JR, Birch DG. Molecular findings in families with an initial diagnosis of autosomal dominant retinitis pigmentosa (adRP). *Mol Vis.* 2017 Jul 20;23:470-481. eCollection 2017.
 294. Jones KD, Wheaton DK, Bowne SJ, Sullivan LS, Birch DG, Chen R, Daiger SP. Next-generation sequencing to solve complex inherited retinal dystrophy: A case series of multiple genes contributing to disease in extended families. *Mol Vis.* 2017 Jul 20;23:470-481. eCollection 2017. PMID:28761320
 295. Schönbach EM, Ibrahim MA, Strauss RW, Birch DG, Cideciyan AV, Hahn GA, Ho A, Kong X, Nasser F, Sunness JS, Zrenner E, Sadda S, West SK, Scholl HPN. Fixation location and stability using the MP1 microperimeter in Stargardt disease: ProgStar Report No 3. *Ophthalmology* 2017; 1(1): 68-76.
 296. Hariri AH, Velaga SB, Girach A, Ip MS, Le PV, Lam BL, Fischer MD, Sankila EM, Pennesi M, Holz FG, MacLaren RE, Birch DG, Hoyng CB, MacDonald IM, Black GC, Tsang SH, Bressler NM, Larsen M, Gorin MB, Webster AR, Sadda SR; For Natural History of the Progression of Choroideremia (NIGHT) Study Group. Measurement and Reproducibility of Preserved Ellipsoid Zone Area and Preserved RPE Area in a Cohort of Eyes with Choroideremia. *Am J Ophthalmol* 2017 May 9 PMID: 28499705.

297. Soens ZT, Branch J, Wu S, Yuan Z, Li Y, Li H, Wang K, Xu M, Rajan L, Motta FL, Simões RT, Lopez-Solache I, Ajlan R, Birch DG, Zhao P, Porto FB, Sallum J, Koenekoop RK, Sui R, Chen R. Leveraging splice-affecting variant predictors and a minigene validation system to identify Mendelian disease-causing variants among exon-capturing variants of uncertain significance. *Hum Mutat.* 2017 Nov;38(11):1521-1533. doi: 10.1002/humu.23294. Epub 2017 Aug 18. PMID:28714225
298. Schönbach EM, Strauss RW, Kong X, Muñoz B, Cideciyan AV, Birch DG, Sunness JS, West SK, Scholl HPN. Metrics and Acquisition Modes for Fixation Stability as a Visual Function Biomarker. *Invest Ophthalmol Vis Sci* 2017 May 1;58(6):BIO268-BIO276. doi: 10.1167/iovs.17-21710. PMID:28973313
299. Bennett LD, Klein M, Locke KG, Kiser K, Birch DG. Dark-adapted chromatic perimetry for measuring rod visual fields in patients with retinitis pigmentosa. *Transl Vis Sci Technol.* 2017 Aug 9;6(4):15. doi: 10.1167/tvst.6.4.15. eCollection 2017 Jul. PMID:28798898.
300. Täger J, Kohl S, Wissinger B, Birch DG, Wheaton DKH, Reuter P. An early nonsense mutation facilitates the expression of a short isoform of CNGA3 by alternative translation initiation. *Exp Eye Res.* 2018 171:48-53.
301. Birch DG, Benz MS, Miller DM, Antoszyk AN, Markoff J, Kozma P, Meunier E, Sergott RC for the Oasis Study Team. Evaluation of Full-Field Electroretinogram Reductions after Ocriciplasmin Treatment: Results of the OASIS Trial ERG Substudy. *Retina* 2018 38:2 364-378.
302. Birch DG, Pennesi M, Lam B, Ianaconne A, Heckenlively, J, Bernstein P, Bremer S, Zilliox P, Francis P. A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa. Submitted.
303. Markoff J, Birch DG, Kozma P for the OASIS study group. Improvement in baseline amplitude of the scotopic b-wave after release of vitreomacular traction (VMT): Further sub-study analysis from the OASIS trial. Submitted.
304. Jayasundera T, Pennesi ME, Birch DG, Ozden-Gurses R, Reichley C, Beasley K, Chulay JD. Prospective evaluation of patients with x-linked retinosis: study design and baseline characteristics. Submitted.
305. Strauss R, Kong X, Bittencourt M, Ho A, Jha A, Schönbach E, Ahmed M, Munoz B, Ervin A, West S, Michaelides M, Birch D, Sahel J, Sunness J, Zrenner E, Bagheri S, Ip M, Sadda S, Scholl H. Scotopic microperimetric assessment of rod function in Stargardt disease (SMART) study. Design and baseline characteristics (Report No. 1). In Press.
306. Fujinami K, Strauss RW, Chiang J, Audo I, Bernstein PS, Birch DG, Jacobson SG, Mansfield BC, Marino MJ, Sahel J-A, Mohand-Daid S, Sunness JS, Traboulsi EI, Zrenner E, Michaelides M, Scholl HP. Genetic characterization of an international large cohort with Stargardt disease: The ProgStar study. In Press.
307. Duncan J, Pierce E, Laster A, Daiger S, Birch D, Ash J, Iannaccone A, Flannery J, Sahel J-A, Weleber R, Zack D, Zarbin M. Inherited Retinal Degenerations: Current Landscape and Knowledge Gaps. *Trans Vision Sci & Tech*, In Press.
308. Pennesi ME, Birch DG, Duncan JL, Bennett J, Girach A. Choroideremia: a high unmet need disease. Submitted.
309. Strauss RW, Muñoz B, Ahmed MI, Bittencourt M, Schönbach E, Michaelides M, Birch DG, Zrenner E, Ervi A-M, Issa PC, Wolfson Y, Shah M, Bagheri S, West S, Scholl HPN. The Progression of Stargardt Disease Type 4 (ProgStar-4) Study; Design and baseline characteristics (*ProgStar-4 Report No. 1*). Submitted.
310. Csaky KG, Patel PJ, Sepah YJ, Birch DG, Do DV, Ip MS, Guymer RH, Luu CD, Gune S, Lin H, Ferrara D. Microperimetry for the assessment of visual function loss in geographic atrophy secondary to age-related macular degeneration. Submitted.
311. Barnes CS, Schuchard RA, Birch DG, Dagnelie G, Koenekoop RK, Bittner AK. Comparison of Goldmann and Semi-automated Kinetic Perimetry in Children and Adults with Retinal Dystrophies. Submitted.

312. Birch D, Lam B, Ong T, Penessi M, Tsang S. Development of adeno-associated virus gene therapy for inherited retinal disease. Submitted.
313. Schönbach EM, Strauss RW, Kong X, Muñoz B, Ibrahim MA, Cideciyan AV, Sunness JS, Birch DG, Hahn G-A, Nasser F, Zrenner E, Sadda SR, West SK, Scholl HPN. Longitudinal changes in fixation location and stability with 12 months in Stargardt disease. In Press.
314. Gregori NZ, Callaway NF, Hoepfner C, Yuan A, Rachitskaya A, Feuer W, Ameri H, Arevalo JF, Augustin AJ, Birch DG, Dagnelie G, Grisanti S, Davis J, Hahn P, Handa JT, Ho A, Huang HS, Humayun MS, Iezzi, Jr. R, Jayasundera KT, Kokame GT, Lam BT, Lim JI, Mandava N, Montezuma SR, de Koo LO, Szurman P, Vajzovic L, Wiedemann P, Weiland J, Yan J, Zacks DN. Retinal Anatomy and Electrode Array Position by Optical Coherence Tomography in Retinitis Pigmentosa Patients after Argus II Implantation: an International Study.